CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | boron atom |
|
Accession: | CHEBI:27560
|
browse the term
|
Definition: | A boron group element atom that has formula B. |
Synonyms: | related_synonym: | 5B; B; Bor; Formula=B; InChI=1S/B; InChIKey=ZOXJGFHDIHLPTG-UHFFFAOYSA-N; SMILES=[B]; boracium; bore; boro; boron |
| alt_id: | CHEBI:22915; CHEBI:3152 |
| xref: | CAS:7440-42-8; KEGG:C06266 |
| xref_mesh: | MESH:D001895 |
| xref: | WebElements:B |
|
|
|
G |
Atrnl1 |
attractin like 1 |
increases expression |
ISO |
Boron results in increased expression of ATRNL1 mRNA |
CTD |
PMID:21625915 |
|
NCBI chr19:57,599,248...58,121,775
Ensembl chr19:57,599,466...58,121,775
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein |
CTD |
PMID:33137424 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein |
CTD |
PMID:33137424 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression |
ISO |
Boron results in increased expression of BGLAP mRNA |
CTD |
PMID:21625915 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
increases expression |
ISO |
Boron results in increased expression of BMP7 mRNA |
CTD |
PMID:21625915 |
|
NCBI chr 2:172,709,805...172,782,114
Ensembl chr 2:172,709,805...172,782,114
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Boron results in increased expression of CASP3 protein modified form |
CTD |
PMID:23462526 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; Boron inhibits the reaction [Dietary Fats results in decreased activity of CAT protein] |
CTD |
PMID:30997025 PMID:36419211 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Boron results in decreased expression of CCND1 protein |
CTD |
PMID:23462526 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
increases expression |
ISO |
Boron results in increased expression of COL1A1 mRNA |
CTD |
PMID:21625915 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Crp |
C-reactive protein, pentraxin-related |
multiple interactions |
ISO |
Boron inhibits the reaction [Dietary Fats results in increased expression of CRP mRNA] |
CTD |
PMID:36419211 |
|
NCBI chr 1:172,525,623...172,527,533
Ensembl chr 1:172,525,622...172,660,598
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein] |
CTD |
PMID:35020164 |
|
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] |
CTD |
PMID:30997025 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] |
CTD |
PMID:35020164 |
|
NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein |
CTD |
PMID:33137424 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] |
CTD |
PMID:30997025 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein] |
CTD |
PMID:35020164 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA] |
CTD |
PMID:30997025 PMID:36419211 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein |
CTD |
PMID:33137424 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein |
CTD |
PMID:33137424 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA] |
CTD |
PMID:30997025 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Boron inhibits the reaction [Dietary Fats results in increased expression of LEP mRNA] |
CTD |
PMID:36419211 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA |
CTD |
PMID:33137424 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Boron inhibits the reaction [Dietary Fats results in decreased expression of PPAR mRNA] |
CTD |
PMID:36419211 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
ISO |
Boron inhibits the reaction [Dietary Fats results in decreased activity of SOD1 protein] |
CTD |
PMID:36419211 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Boron inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] |
CTD |
PMID:30997025 PMID:36419211 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Nphs1 |
nephrosis 1, nephrin |
increases expression |
EXP |
BD4 increases expression of Nphs1 mRNA in podocytes |
RGD |
PMID:22125642 |
RGD:40902998 |
NCBI chr 7:30,157,259...30,188,048
Ensembl chr 7:30,157,740...30,186,648
|
|
G |
Synpo |
synaptopodin |
increases expression |
EXP |
BD4 increases expression of Synpo mRNA in podocytes |
RGD |
PMID:22125642 |
RGD:40902998 |
NCBI chr18:60,727,053...60,793,241
Ensembl chr18:60,727,045...60,793,214
|
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] |
CTD |
PMID:29883672 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] |
CTD |
PMID:29883672 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] |
CTD |
PMID:29883672 |
|
NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] |
CTD |
PMID:29883672 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cd28 |
CD28 antigen |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:14607919 |
|
NCBI chr 1:60,785,547...60,812,521
Ensembl chr 1:60,755,959...60,812,518
|
|
G |
Grm1 |
glutamate receptor, metabotropic 1 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] |
CTD |
PMID:14622174 |
|
NCBI chr10:10,561,803...10,958,126
Ensembl chr10:10,561,803...10,958,100
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
multiple interactions |
ISO |
2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein] |
CTD |
PMID:33408296 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
affects transport |
ISO |
ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene |
CTD |
PMID:12739759 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] |
CTD |
PMID:28544013 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions |
ISO |
boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of ACSL4 protein] |
CTD |
PMID:38108610 |
|
NCBI chr X:141,100,989...141,173,792
Ensembl chr X:141,100,989...141,173,531
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
decreases expression |
ISO |
boric acid results in decreased expression of ACTA2 protein |
CTD |
PMID:25637568 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] |
CTD |
PMID:28285642 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
increases expression |
EXP |
boric acid results in increased expression of AKT1 mRNA |
CTD |
PMID:31368021 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Arg1 |
arginase, liver |
decreases activity |
ISO |
boric acid results in decreased activity of ARG1 protein |
CTD |
PMID:21232540 |
|
NCBI chr10:24,791,105...24,803,368
Ensembl chr10:24,791,119...24,803,382
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein |
CTD |
PMID:25425213 PMID:27587023 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
boric acid results in increased cleavage of and affects the localization of ATF6 protein |
CTD |
PMID:27587023 |
|
NCBI chr 1:170,532,026...170,696,414
Ensembl chr 1:170,532,243...170,695,340
|
|
G |
Bax |
BCL2-associated X protein |
decreases expression increases expression multiple interactions |
EXP ISO |
boric acid results in decreased expression of BAX mRNA boric acid results in increased expression of BAX mRNA [boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein |
CTD |
PMID:31368021 PMID:33137424 PMID:34175401 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
increases expression decreases expression multiple interactions |
EXP ISO |
boric acid results in increased expression of BCL2 mRNA boric acid results in decreased expression of BCL2 mRNA [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein |
CTD |
PMID:31368021 PMID:33137424 PMID:34175401 |
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression |
ISO |
boric acid results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:34175401 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
boric acid results in increased expression of BID mRNA |
CTD |
PMID:34175401 |
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
boric acid results in increased expression of CALR mRNA |
CTD |
PMID:27587023 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression decreases expression |
ISO EXP |
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA] boric acid results in increased expression of CASP3 mRNA boric acid results in decreased expression of CASP3 mRNA |
CTD |
PMID:31368021 PMID:31823256 PMID:34175401 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
boric acid results in increased expression of CASP9 mRNA |
CTD |
PMID:34175401 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO |
[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein] boric acid results in decreased activity of CAT protein boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein] |
CTD |
PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression multiple interactions |
EXP |
boric acid results in increased expression of CCND1 mRNA boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein] |
CTD |
PMID:28285642 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]] |
CTD |
PMID:28285642 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Col1a2 |
collagen, type I, alpha 2 |
affects expression |
EXP |
boric acid affects the expression of COL1A2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 6:4,505,618...4,541,543
Ensembl chr 6:4,504,814...4,541,544
|
|
G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
increases expression |
ISO |
boric acid results in increased expression of CSF2 protein |
CTD |
PMID:27206737 |
|
NCBI chr11:54,138,096...54,140,725
Ensembl chr11:54,138,097...54,140,493
|
|
G |
Csf3 |
colony stimulating factor 3 (granulocyte) |
increases expression |
ISO |
boric acid results in increased expression of CSF3 protein |
CTD |
PMID:27206737 |
|
NCBI chr11:98,591,287...98,594,457
Ensembl chr11:98,592,089...98,594,455
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of CST3 protein] |
CTD |
PMID:35020164 |
|
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] |
CTD |
PMID:28285642 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases expression |
ISO |
boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein |
CTD |
PMID:27587023 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Des |
desmin |
affects expression |
ISO |
boric acid affects the expression of DES mRNA |
CTD |
PMID:25637568 |
|
NCBI chr 1:75,336,936...75,345,223
Ensembl chr 1:75,336,973...75,345,223
|
|
G |
Dvl2 |
dishevelled segment polarity protein 2 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr11:69,891,418...69,900,935
Ensembl chr11:69,891,421...69,903,127
|
|
G |
Edem1 |
ER degradation enhancer, mannosidase alpha-like 1 |
increases expression |
ISO |
boric acid results in increased expression of EDEM1 mRNA |
CTD |
PMID:27587023 |
|
NCBI chr 6:108,800,984...108,836,317
Ensembl chr 6:108,805,602...108,836,317
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:30196486 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
increases phosphorylation multiple interactions |
ISO EXP |
boric acid results in increased phosphorylation of EIF2S1 protein EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:25425213 PMID:27587023 PMID:30196486 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Fabp4 |
fatty acid binding protein 4, adipocyte |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]] |
CTD |
PMID:28285642 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein] |
CTD |
PMID:28285642 |
|
NCBI chr 3:37,402,616...37,464,255
Ensembl chr 3:37,402,495...37,464,257
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases expression |
ISO |
boric acid results in increased expression of FGF7 protein |
CTD |
PMID:27206737 |
|
NCBI chr 2:125,876,578...125,933,105
Ensembl chr 2:125,876,578...125,933,105
|
|
G |
Fn1 |
fibronectin 1 |
affects expression increases expression |
ISO EXP |
boric acid affects the expression of FN1 mRNA boric acid results in increased expression of FN1 mRNA |
CTD |
PMID:27206737 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
EXP |
boric acid results in decreased expression of GAPDH protein |
CTD |
PMID:28285642 |
|
NCBI chr 6:125,138,812...125,143,450
Ensembl chr 6:125,138,678...125,143,430
|
|
G |
Gas6 |
growth arrest specific 6 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein] |
CTD |
PMID:28285642 |
|
NCBI chr 8:13,515,374...13,544,535
Ensembl chr 8:13,515,374...13,544,490
|
|
G |
Gck |
glucokinase |
increases expression |
EXP |
boric acid results in increased expression of GCK mRNA |
CTD |
PMID:31368021 |
|
NCBI chr11:5,850,816...5,900,081
Ensembl chr11:5,850,820...5,900,081
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO EXP |
boric acid results in increased expression of GCLC mRNA EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA] |
CTD |
PMID:30196486 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] |
CTD |
PMID:30997025 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of GPX4 protein] |
CTD |
PMID:38108610 |
|
NCBI chr10:79,883,000...79,892,273
Ensembl chr10:79,883,000...79,892,273
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of HAVCR1 protein] |
CTD |
PMID:35020164 |
|
NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405
|
|
G |
Herpud1 |
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 |
increases expression |
ISO |
boric acid results in increased expression of HERPUD1 mRNA |
CTD |
PMID:27587023 |
|
NCBI chr 8:95,113,057...95,121,999
Ensembl chr 8:95,113,066...95,122,005
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO EXP |
boric acid results in increased expression of HMOX1 mRNA |
CTD |
PMID:30196486 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hoxa6 |
homeobox A6 |
affects expression |
ISO |
boric acid affects the expression of HOXA6 mRNA |
CTD |
PMID:12749385 |
|
NCBI chr 6:52,181,838...52,185,652
Ensembl chr 6:52,183,268...52,185,702
|
|
G |
Hoxc6 |
homeobox C6 |
affects expression |
ISO |
boric acid affects the expression of HOXC6 mRNA |
CTD |
PMID:12749385 |
|
NCBI chr15:102,906,658...102,920,314
Ensembl chr15:102,906,689...102,920,313
|
|
G |
Hspa5 |
heat shock protein 5 |
increases expression |
ISO |
boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein |
CTD |
PMID:25425213 PMID:27587023 |
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IFNG mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein] |
CTD |
PMID:29913234 PMID:30368975 PMID:32179172 PMID:33137424 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL10 mRNA |
CTD |
PMID:30997025 PMID:32179172 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [Acetaminophen results in increased expression of IL18 protein] |
CTD |
PMID:35020164 |
|
NCBI chr 9:50,466,000...50,493,141
Ensembl chr 9:50,466,127...50,493,140
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL1B mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] |
CTD |
PMID:29913234 PMID:30368975 PMID:30997025 PMID:32179172 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein |
CTD |
PMID:33137424 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il4 |
interleukin 4 |
increases expression multiple interactions |
EXP ISO |
boric acid results in increased expression of IL4 mRNA [boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein |
CTD |
PMID:31368021 PMID:33137424 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA] [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of IL6 mRNA |
CTD |
PMID:28285642 PMID:30997025 PMID:32179172 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins1 |
insulin I |
increases expression |
EXP |
boric acid results in increased expression of INS1 mRNA |
CTD |
PMID:31368021 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
multiple interactions increases expression |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] boric acid results in increased expression of INS2 mRNA |
CTD |
PMID:28285642 PMID:31368021 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Klf5 |
Kruppel-like transcription factor 5 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr14:99,536,127...99,550,848
Ensembl chr14:99,536,127...99,552,472
|
|
G |
Lama5 |
laminin, alpha 5 |
increases expression |
EXP ISO |
boric acid results in increased expression of LAMA5 mRNA |
CTD |
PMID:27206737 |
|
NCBI chr 2:179,818,166...179,867,652
Ensembl chr 2:179,818,166...179,867,652
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein |
CTD |
PMID:28285642 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Lipe |
lipase, hormone sensitive |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr 7:25,078,952...25,097,911
Ensembl chr 7:25,078,952...25,098,135
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:28285642 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:28285642 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mir130a |
microRNA 130a |
decreases expression |
ISO |
boric acid results in decreased expression of MIR130A mRNA |
CTD |
PMID:34175401 |
|
NCBI chr 2:84,571,459...84,571,522
Ensembl chr 2:84,571,459...84,571,522
|
|
G |
Mir200a |
microRNA 200a |
decreases expression |
ISO |
boric acid results in decreased expression of MIR200A mRNA |
CTD |
PMID:34175401 |
|
NCBI chr 4:156,139,353...156,139,442
Ensembl chr 4:156,139,353...156,139,442
|
|
G |
Mir21a |
microRNA 21a |
decreases expression |
ISO |
boric acid results in decreased expression of MIR21 mRNA |
CTD |
PMID:34175401 |
|
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mir224 |
microRNA 224 |
decreases expression |
ISO |
boric acid results in decreased expression of MIR224 mRNA |
CTD |
PMID:34175401 |
|
NCBI chr X:71,304,637...71,304,718
Ensembl chr X:71,304,637...71,304,718
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
EXP |
boric acid results in decreased expression of MMP2 protein |
CTD |
PMID:28285642 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Myh1 |
myosin, heavy polypeptide 1, skeletal muscle, adult |
affects expression |
ISO |
boric acid affects the expression of MYH1 mRNA |
CTD |
PMID:25637568 |
|
NCBI chr11:67,090,922...67,115,401
Ensembl chr11:67,090,878...67,115,401
|
|
G |
Myod1 |
myogenic differentiation 1 |
affects expression decreases expression |
ISO |
boric acid affects the expression of MYOD1 mRNA boric acid results in decreased expression of MYOD1 protein |
CTD |
PMID:25637568 |
|
NCBI chr 7:46,025,898...46,028,516
Ensembl chr 7:46,025,898...46,028,523
|
|
G |
Myog |
myogenin |
affects expression |
ISO |
boric acid affects the expression of MYOG mRNA |
CTD |
PMID:25637568 |
|
NCBI chr 1:134,217,742...134,220,286
Ensembl chr 1:134,217,727...134,220,286
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
affects localization multiple interactions |
EXP ISO |
boric acid affects the localization of NFE2L2 protein EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein] |
CTD |
PMID:30196486 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions affects expression |
ISO |
boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA] boric acid affects the expression of NFKB1 mRNA |
CTD |
PMID:31823256 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP |
boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:27206737 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
increases expression |
ISO |
boric acid results in increased expression of NQO1 mRNA |
CTD |
PMID:30196486 |
|
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression multiple interactions |
ISO |
boric acid results in increased expression of PCNA protein [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA |
CTD |
PMID:17943231 PMID:33137424 |
|
NCBI chr 2:132,091,206...132,095,100
Ensembl chr 2:132,091,082...132,095,234
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
increases expression |
EXP |
boric acid results in increased expression of PDX1 mRNA |
CTD |
PMID:31368021 |
|
NCBI chr 5:147,206,907...147,212,658
Ensembl chr 5:147,206,769...147,212,658
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] |
CTD |
PMID:28285642 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein |
CTD |
PMID:27587023 |
|
NCBI chr 7:45,172,341...45,175,692
Ensembl chr 7:45,172,340...45,175,692
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27206737 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein] |
CTD |
PMID:29913234 PMID:30368975 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Runx2 |
runt related transcription factor 2 |
affects expression |
EXP |
boric acid affects the expression of RUNX2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Slc2a2 |
solute carrier family 2 (facilitated glucose transporter), member 2 |
increases expression |
EXP |
boric acid results in increased expression of SLC2A2 mRNA |
CTD |
PMID:31368021 |
|
NCBI chr 3:28,752,052...28,782,510
Ensembl chr 3:28,752,052...28,785,508
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] |
CTD |
PMID:28285642 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc4a2 |
solute carrier family 4 (anion exchanger), member 2 |
increases expression |
ISO |
boric acid results in increased expression of SLC4A2 mRNA |
CTD |
PMID:22576912 |
|
NCBI chr 5:24,628,834...24,645,945
Ensembl chr 5:24,628,835...24,645,948
|
|
G |
Slc4a3 |
solute carrier family 4 (anion exchanger), member 3 |
increases expression |
ISO |
boric acid results in increased expression of SLC4A3 mRNA |
CTD |
PMID:22576912 |
|
NCBI chr 1:75,522,688...75,536,075
Ensembl chr 1:75,522,910...75,538,816
|
|
G |
Sparc |
secreted acidic cysteine rich glycoprotein |
affects expression |
EXP |
boric acid affects the expression of SPARC mRNA |
CTD |
PMID:24704097 |
|
NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:28285642 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Syvn1 |
synovial apoptosis inhibitor 1, synoviolin |
decreases expression |
ISO |
boric acid results in decreased expression of SYVN1 mRNA |
CTD |
PMID:27587023 |
|
NCBI chr19:6,096,586...6,103,748
Ensembl chr19:6,096,606...6,103,742
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC mRNA]; boric acid inhibits the reaction [amyloid beta-protein (1-42) results in increased expression of TFRC protein] |
CTD |
PMID:38108610 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO EXP |
boric acid results in increased expression of TGFB1 protein boric acid results in increased expression of TGFB1 mRNA |
CTD |
PMID:27206737 PMID:31368021 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression increases secretion increases expression |
ISO |
boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] boric acid results in decreased expression of TNF mRNA [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; [Food Preservatives results in increased abundance of boric acid] which results in increased expression of TNF mRNA; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein] boric acid results in increased secretion of TNF protein boric acid results in increased expression of TNF mRNA |
CTD |
PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 PMID:31823256 PMID:32179172 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
multiple interactions |
EXP |
boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein] |
CTD |
PMID:28285642 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Trp53 |
transformation related protein 53 |
decreases expression |
EXP |
boric acid results in decreased expression of TRP53 mRNA |
CTD |
PMID:31368021 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
boric acid results in increased expression of XBP1 mRNA |
CTD |
PMID:27587023 |
|
NCBI chr11:5,470,641...5,475,993
Ensembl chr11:5,470,659...5,475,893
|
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
decreases activity |
ISO |
Boric Acids analog results in decreased activity of GGT1 protein |
CTD |
PMID:6149445 |
|
NCBI chr10:75,396,910...75,422,027
Ensembl chr10:75,397,438...75,422,034
|
|
G |
Muc1 |
mucin 1, transmembrane |
decreases expression |
ISO |
Boric Acids results in decreased expression of MUC1 mRNA |
CTD |
PMID:21060261 |
|
NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
|
|
G |
Muc16 |
mucin 16 |
decreases expression |
ISO |
Boric Acids results in decreased expression of MUC16 mRNA |
CTD |
PMID:21060261 |
|
NCBI chr 9:18,406,741...18,586,117
Ensembl chr 9:18,406,751...18,585,826
|
|
|
G |
1110059E24Rik |
RIKEN cDNA 1110059E24 gene |
increases expression |
ISO |
Bortezomib results in increased expression of C9ORF85 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:21,574,677...21,630,155
Ensembl chr19:21,558,566...21,630,340
|
|
G |
1810037I17Rik |
RIKEN cDNA 1810037I17 gene |
decreases expression |
ISO |
Bortezomib results in decreased expression of C4ORF3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:122,718,046...122,719,843
Ensembl chr 3:122,717,852...122,719,833
|
|
G |
4933434E20Rik |
RIKEN cDNA 4933434E20 gene |
decreases expression |
ISO |
Bortezomib results in decreased expression of C1ORF43 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:89,958,941...89,969,754
Ensembl chr 3:89,958,943...89,970,648 Ensembl chr 3:89,958,943...89,970,648
|
|
G |
Abca2 |
ATP-binding cassette, sub-family A member 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCA2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:25,318,611...25,338,556
Ensembl chr 2:25,318,715...25,338,552
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
multiple interactions decreases expression decreases activity |
ISO EXP |
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein]; Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein] [Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]] Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein Bortezomib results in decreased activity of ABCB1 protein |
CTD |
PMID:25576094 PMID:30482226 PMID:33775688 PMID:34915026 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcc1 |
ATP-binding cassette, sub-family C member 1 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of ABCC1 mRNA [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein |
CTD |
PMID:20977926 PMID:33775688 |
|
NCBI chr16:14,179,317...14,292,743
Ensembl chr16:14,179,422...14,293,601
|
|
G |
Abcc2 |
ATP-binding cassette, sub-family member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of ABCC2 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr19:43,770,747...43,826,771
Ensembl chr19:43,770,631...43,829,179
|
|
G |
Abcc4 |
ATP-binding cassette, sub-family C member 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ABCC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:118,720,104...118,945,475
Ensembl chr14:118,720,104...118,943,631
|
|
G |
Abhd16a |
abhydrolase domain containing 16A |
increases expression |
ISO |
Bortezomib results in increased expression of ABHD16A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:35,308,210...35,321,963
Ensembl chr17:35,308,239...35,321,963
|
|
G |
Abhd2 |
abhydrolase domain containing 2 |
increases expression |
ISO |
Bortezomib results in increased expression of ABHD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:78,923,002...79,015,257
Ensembl chr 7:78,922,947...79,015,256
|
|
G |
Abi1 |
abl interactor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ABI1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:22,830,085...22,930,207
Ensembl chr 2:22,830,085...22,930,253
|
|
G |
Abl1 |
c-abl oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] |
CTD |
PMID:15039284 PMID:17495969 PMID:21195056 |
|
NCBI chr 2:31,578,256...31,697,105
Ensembl chr 2:31,578,388...31,694,239
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
[Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form |
CTD |
PMID:20454656 |
|
NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790
|
|
G |
Acot7 |
acyl-CoA thioesterase 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ACOT7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:152,258,872...152,356,312
Ensembl chr 4:152,262,591...152,356,312
|
|
G |
Adam10 |
a disintegrin and metallopeptidase domain 10 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ADAM10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:70,586,133...70,687,511
Ensembl chr 9:70,586,279...70,687,511
|
|
G |
Adm |
adrenomedullin |
multiple interactions decreases expression |
ISO |
Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA] Bortezomib results in decreased expression of ADM mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 7:110,226,864...110,229,027
Ensembl chr 7:110,226,868...110,229,027
|
|
G |
Aff1 |
AF4/FMR2 family, member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of AFF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:103,840,307...104,003,188
Ensembl chr 5:103,840,240...104,003,188
|
|
G |
Aff4 |
AF4/FMR2 family, member 4 |
increases expression |
ISO |
Bortezomib results in increased expression of AFF4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:53,240,807...53,312,657
Ensembl chr11:53,241,660...53,312,657
|
|
G |
Afg2a |
AFG2 AAA ATPase homolog A |
increases expression |
ISO |
Bortezomib results in increased expression of AFG2A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:37,474,052...37,633,245
Ensembl chr 3:37,474,045...37,633,245
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of AGER mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910
|
|
G |
Agk |
acylglycerol kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:40,302,010...40,378,723
Ensembl chr 6:40,302,106...40,373,696
|
|
G |
Agrn |
agrin |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGRN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:156,249,747...156,281,997
Ensembl chr 4:156,249,747...156,281,945
|
|
G |
Agtpbp1 |
ATP/GTP binding protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of AGTPBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:59,597,348...59,705,184
Ensembl chr13:59,593,556...59,733,041
|
|
G |
Agtrap |
angiotensin II, type I receptor-associated protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of AGTRAP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:148,161,518...148,172,521
Ensembl chr 4:148,161,518...148,172,488
|
|
G |
AI837181 |
expressed sequence AI837181 |
decreases expression |
ISO |
Bortezomib results in decreased expression of C11ORF68 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:5,475,172...5,477,345
Ensembl chr19:5,475,172...5,477,341
|
|
G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
affects localization multiple interactions |
ISO |
Bortezomib affects the localization of AIFM1 protein [Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein |
CTD |
PMID:12893773 PMID:16024631 |
|
NCBI chr X:47,563,821...47,602,440
Ensembl chr X:47,563,821...47,602,440
|
|
G |
Aifm2 |
apoptosis-inducing factor, mitochondrion-associated 2 |
increases expression |
ISO |
Bortezomib results in increased expression of AIFM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:61,551,042...61,575,474
Ensembl chr10:61,551,042...61,575,039
|
|
G |
Aim2 |
absent in melanoma 2 |
increases expression |
ISO |
Bortezomib results in increased expression of AIM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:173,177,105...173,293,606
Ensembl chr 1:173,178,445...173,293,606
|
|
G |
Airim |
AFG2 interacting ribosome maturation factor |
increases expression |
ISO |
Bortezomib results in increased expression of AIRIM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:124,830,777...124,838,454
Ensembl chr 4:124,830,841...124,838,449
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein |
CTD |
PMID:21215737 |
|
NCBI chr 6:34,280,865...34,294,424
Ensembl chr 6:34,279,369...34,294,413
|
|
G |
Akr1b10 |
aldo-keto reductase family 1, member B10 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein |
CTD |
PMID:21215737 |
|
NCBI chr 6:34,361,182...34,373,884
Ensembl chr 6:34,361,153...34,373,885
|
|
G |
Akr1c18 |
aldo-keto reductase family 1, member C18 |
increases expression |
ISO |
Bortezomib results in increased expression of AKR1C3 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr13:4,182,614...4,200,645
Ensembl chr13:4,182,614...4,200,653
|
|
G |
Akr1c20 |
aldo-keto reductase family 1, member C20 |
multiple interactions increases expression |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA Bortezomib results in increased expression of AKR1C1 mRNA |
CTD |
PMID:21215737 PMID:25913414 |
|
NCBI chr13:4,536,855...4,573,353
Ensembl chr13:4,536,848...4,573,344
|
|
G |
Akr1c21 |
aldo-keto reductase family 1, member C21 |
affects expression |
ISO |
Bortezomib affects the expression of AKR1C2 mRNA |
CTD |
PMID:21215737 |
|
NCBI chr13:4,624,074...4,636,542
Ensembl chr13:4,624,074...4,636,540
|
|
G |
Akr7a5 |
aldo-keto reductase family 7, member A5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 4:139,038,005...139,046,097
Ensembl chr 4:139,038,055...139,045,737
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form] Bortezomib results in decreased activity of AKT1 protein |
CTD |
PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 PMID:18701494 PMID:19261616 PMID:19457607 PMID:20701607 PMID:21472287 More...
|
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Alad |
aminolevulinate, delta-, dehydratase |
decreases activity multiple interactions |
EXP |
Bortezomib results in decreased activity of ALAD protein Curcumin inhibits the reaction [Bortezomib results in decreased activity of ALAD protein] |
CTD |
PMID:25352650 |
|
NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:40,538,701...40,576,907
Ensembl chr19:40,538,701...40,576,907
|
|
G |
Aldh5a1 |
aldhehyde dehydrogenase family 5, subfamily A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644 Ensembl chr13:25,091,562...25,121,644
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase family 6, subfamily A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ALDH6A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase |
increases response to substance |
ISO |
ALOX12 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr11:70,132,283...70,146,206
Ensembl chr11:70,132,283...70,146,179
|
|
G |
Anapc11 |
anaphase promoting complex subunit 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ANAPC11 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr11:120,489,247...120,499,024
Ensembl chr11:120,489,247...120,499,024
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
decreases expression increases expression |
ISO |
Bortezomib results in decreased expression of ANAPC5 mRNA Bortezomib results in increased expression of ANAPC5 mRNA |
CTD |
PMID:17895889 PMID:20977926 |
|
NCBI chr 5:122,925,522...122,960,402
Ensembl chr 5:122,925,522...122,959,402
|
|
G |
Ankrd9 |
ankyrin repeat domain 9 |
increases expression |
ISO |
Bortezomib results in increased expression of ANKRD9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:110,942,854...110,945,516
Ensembl chr12:110,941,787...110,945,474
|
|
G |
Ano10 |
anoctamin 10 |
increases expression |
ISO |
Bortezomib results in increased expression of ANO10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:122,004,958...122,123,440
Ensembl chr 9:122,004,940...122,123,489
|
|
G |
Ap1s1 |
adaptor protein complex AP-1, sigma 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of AP1S1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:137,063,852...137,074,917
Ensembl chr 5:137,063,847...137,074,989
|
|
G |
Ap2a1 |
adaptor-related protein complex 2, alpha 1 subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of AP2A1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:44,549,797...44,578,914
Ensembl chr 7:44,549,797...44,578,920
|
|
G |
Apobr |
apolipoprotein B receptor |
decreases expression |
ISO |
Bortezomib results in decreased expression of APOBR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:126,184,092...126,188,297
Ensembl chr 7:126,184,114...126,188,284
|
|
G |
Apol9a |
apolipoprotein L 9a |
decreases expression |
ISO |
Bortezomib results in decreased expression of APOL4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:77,287,989...77,295,280
Ensembl chr15:77,287,989...77,295,335
|
|
G |
Apool |
apolipoprotein O-like |
increases expression |
ISO |
Bortezomib results in increased expression of APOOL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:111,221,049...111,282,452
Ensembl chr X:111,221,031...111,282,452
|
|
G |
Aqp3 |
aquaporin 3 |
increases expression |
ISO |
Bortezomib results in increased expression of AQP3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:41,092,724...41,098,183
Ensembl chr 4:41,092,722...41,098,183
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr X:97,192,363...97,366,824
Ensembl chr X:97,192,375...97,366,821
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
increases expression |
ISO |
Bortezomib results in increased expression of ARF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:69,418,924...69,422,754
Ensembl chr12:69,418,924...69,420,557
|
|
G |
Arfgap1 |
ADP-ribosylation factor GTPase activating protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARFGAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:180,608,290...180,624,319
Ensembl chr 2:180,609,018...180,624,319
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARHGAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:91,480,463...91,502,670
Ensembl chr 2:91,480,205...91,502,671
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:120,468,925...120,472,450
Ensembl chr11:120,468,930...120,472,450
|
|
G |
Arid3b |
AT-rich interaction domain 3B |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 9:57,697,636...57,744,130
Ensembl chr 9:57,697,636...57,744,076
|
|
G |
Arl4c |
ADP-ribosylation factor-like 4C |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARL4C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:88,625,947...88,629,913
Ensembl chr 1:88,600,847...88,629,943
|
|
G |
Arl8a |
ADP-ribosylation factor-like 8A |
increases expression |
ISO |
Bortezomib results in increased expression of ARL8A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:135,074,572...135,084,007
Ensembl chr 1:135,074,562...135,084,007
|
|
G |
Arrb1 |
arrestin, beta 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ARRB1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:99,184,356...99,255,979
Ensembl chr 7:99,184,673...99,255,978
|
|
G |
Asap1 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ASAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:63,958,704...64,254,922
Ensembl chr15:63,958,706...64,254,768
|
|
G |
Ate1 |
arginyltransferase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ATE1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:129,993,219...130,122,349
Ensembl chr 7:129,993,223...130,122,099
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases phosphorylation increases expression |
ISO |
pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein] Bortezomib results in increased expression of ATF2 mRNA |
CTD |
PMID:12393500 PMID:20977926 |
|
NCBI chr 2:73,646,853...73,723,094
Ensembl chr 2:73,646,853...73,722,983
|
|
G |
Atf3 |
activating transcription factor 3 |
increases response to substance multiple interactions increases expression |
ISO EXP |
ATF3 results in increased susceptibility to Bortezomib [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA] Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein |
CTD |
PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA] Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein ATF4 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16928686 PMID:20022965 |
|
NCBI chr15:80,139,385...80,141,746
Ensembl chr15:80,139,385...80,141,742
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Bortezomib results in increased expression of ATF5 mRNA |
CTD |
PMID:17898295 |
|
NCBI chr 7:44,461,680...44,466,082
Ensembl chr 7:44,461,680...44,466,082
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
EXP |
ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] |
CTD |
PMID:22842577 |
|
NCBI chr10:44,144,325...44,240,295
Ensembl chr10:44,144,354...44,240,287
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions increases cleavage |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] |
CTD |
PMID:12393500 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atp1a3 |
ATPase, Na+/K+ transporting, alpha 3 polypeptide |
decreases expression |
ISO |
Bortezomib results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383
|
|
G |
Atp2a1 |
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 |
multiple interactions affects response to substance |
ISO |
ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1] ATP2A1 protein affects the susceptibility to Bortezomib |
CTD |
PMID:25576094 |
|
NCBI chr 7:126,045,032...126,062,245
Ensembl chr 7:126,045,030...126,062,280
|
|
G |
Atp6v0e |
ATPase, H+ transporting, lysosomal V0 subunit E |
increases expression |
ISO |
Bortezomib results in increased expression of ATP6V0E1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:26,895,370...26,918,621
Ensembl chr17:26,882,205...26,918,621
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
Bortezomib results in decreased expression of B2M protein |
CTD |
PMID:17204182 |
|
NCBI chr 2:121,978,168...121,983,563
Ensembl chr 2:121,978,167...121,983,564
|
|
G |
B3gnt2 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of B3GNT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:22,784,739...22,810,336
Ensembl chr11:22,709,738...22,810,961
|
|
G |
B4galt6 |
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 |
increases expression |
ISO |
Bortezomib results in increased expression of B4GALT6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:20,817,656...20,879,461
Ensembl chr18:20,817,656...20,879,461
|
|
G |
Bag3 |
BCL2-associated athanogene 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BAG3 mRNA |
CTD |
PMID:15509775 PMID:17659339 PMID:20471514 |
|
NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
ISO EXP |
[nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein] Bortezomib results in increased expression of BAK1 protein |
CTD |
PMID:12902978 PMID:17326159 PMID:20850924 |
|
NCBI chr17:27,238,786...27,247,601
Ensembl chr17:27,238,784...27,247,983
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
increases response to substance |
ISO |
BARD1 mutant form results in increased susceptibility to Bortezomib |
CTD |
PMID:25522274 |
|
NCBI chr 1:71,066,694...71,142,300
Ensembl chr 1:71,066,657...71,142,305
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions increases expression |
ISO |
[Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]] Bortezomib results in increased expression of BAX protein |
CTD |
PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 |
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein |
CTD |
PMID:17898295 PMID:20051518 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bbln |
bublin coiled coil protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of BBLN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:32,269,120...32,271,877
Ensembl chr 2:32,267,109...32,271,950
|
|
G |
BC005537 |
cDNA sequence BC005537 |
increases expression |
ISO |
Bortezomib results in increased expression of C6ORF62 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:24,985,640...24,996,882
Ensembl chr13:24,985,640...25,000,180
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
multiple interactions decreases expression increases cleavage increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein |
CTD |
PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 PMID:17156654 PMID:17326159 PMID:17327374 PMID:17351739 PMID:17895889 PMID:18718063 PMID:18928586 PMID:20051518 PMID:20383943 PMID:20471514 PMID:21302442 PMID:24377552 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2a1b |
B cell leukemia/lymphoma 2 related protein A1b |
multiple interactions increases expression |
ISO |
[romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein Bortezomib results in increased expression of BCL2A1A protein |
CTD |
PMID:18223231 PMID:20051518 |
|
NCBI chr 9:89,081,326...89,089,891
Ensembl chr 9:89,081,262...89,089,880
|
|
G |
Bcl2l1 |
BCL2-like 1 |
multiple interactions decreases expression increases expression increases cleavage decreases response to substance |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [Vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [Vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; Bortezomib promotes the reaction [capillarisin results in decreased expression of BCL2L1 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein] Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein Bortezomib results in increased expression of BCL2L1 protein BCL2L1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 PMID:16617327 PMID:16904634 PMID:17326159 PMID:17327374 PMID:17351739 PMID:18223231 PMID:19100720 PMID:20051518 PMID:24333736 More...
|
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression increases activity increases response to substance |
ISO |
[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]; Bortezomib inhibits the reaction [Arsenic Trioxide results in increased degradation of BCL2L11 protein] Bortezomib results in increased expression of BCL2L11 protein Bortezomib results in increased activity of BCL2L11 protein BCL2L11 results in increased susceptibility to Bortezomib |
CTD |
PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 PMID:36509116 More...
|
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Bcl2l2 |
BCL2-like 2 |
increases expression |
ISO |
Bortezomib results in increased expression of BCL2L2 mRNA |
CTD |
PMID:18928586 |
|
NCBI chr14:55,120,900...55,125,691
Ensembl chr14:55,120,834...55,125,691
|
|
G |
Bcl3 |
B cell leukemia/lymphoma 3 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA Bortezomib results in decreased expression of BCL3 mRNA |
CTD |
PMID:20471514 PMID:20977926 |
|
NCBI chr 7:19,542,387...19,556,691
Ensembl chr 7:19,542,387...19,556,695
|
|
G |
Bcl6 |
B cell leukemia/lymphoma 6 |
increases expression |
ISO |
Bortezomib results in increased expression of BCL6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:23,780,058...23,807,602
Ensembl chr16:23,783,802...23,807,602
|
|
G |
Bcl7a |
B cell CLL/lymphoma 7A |
decreases expression |
ISO |
Bortezomib results in decreased expression of BCL7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:123,482,511...123,512,146
Ensembl chr 5:123,481,897...123,513,055
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
decreases expression |
ISO |
Bortezomib results in decreased expression of BCR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:74,896,384...75,020,753
Ensembl chr10:74,896,424...75,020,753
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions decreases response to substance |
ISO |
BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] BECN1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:22842577 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage multiple interactions |
ISO |
Bortezomib results in increased cleavage of BID protein [Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein] |
CTD |
PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 PMID:17898295 PMID:19261616 More...
|
|
NCBI chr 6:120,870,080...120,894,074
Ensembl chr 6:120,868,891...120,893,814
|
|
G |
Bik |
BCL2-interacting killer |
increases response to substance increases expression increases activity |
ISO |
BIK results in increased susceptibility to Bortezomib Bortezomib results in increased expression of BIK protein Bortezomib results in increased activity of BIK protein |
CTD |
PMID:16446371 PMID:18566236 |
|
NCBI chr15:83,410,992...83,428,836
Ensembl chr15:83,411,063...83,428,835
|
|
G |
Bin1 |
bridging integrator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of BIN1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr18:32,509,671...32,568,793
Ensembl chr18:32,510,283...32,568,790
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BIRC2 protein [geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein |
CTD |
PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 |
|
NCBI chr 9:7,818,227...7,837,123
Ensembl chr 9:7,818,228...7,837,065
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression increases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BIRC3 protein Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA |
CTD |
PMID:17626072 PMID:24085292 PMID:25522274 |
|
NCBI chr 9:7,848,698...7,873,199
Ensembl chr 9:7,848,700...7,873,187
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression multiple interactions increases expression |
ISO |
Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein [Irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein; Bortezomib promotes the reaction [capillarisin results in decreased expression of BIRC5 protein] Bortezomib results in increased expression of BIRC5 protein |
CTD |
PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 PMID:19636294 PMID:20977926 PMID:24333736 More...
|
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] |
CTD |
PMID:21867610 |
|
NCBI chr 2:180,570,402...180,575,803
Ensembl chr 2:180,570,816...180,575,803
|
|
G |
Blk |
B lymphoid kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of BLK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:63,610,286...63,654,636
Ensembl chr14:63,610,285...63,654,486
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
Bortezomib results in increased expression of BLVRB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:27,147,403...27,165,406
Ensembl chr 7:27,147,403...27,165,569
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of BNIP3 protein |
CTD |
PMID:20110775 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Brca1 |
breast cancer 1, early onset |
decreases expression increases response to substance decreases ubiquitination multiple interactions |
ISO EXP |
Bortezomib results in decreased expression of BRCA1 mRNA BRCA1 mutant form results in increased susceptibility to Bortezomib Bortezomib results in decreased ubiquitination of BRCA1 protein [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein] BRCA1 gene mutant form results in increased susceptibility to Bortezomib BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib] |
CTD |
PMID:21917757 PMID:25522274 |
|
NCBI chr11:101,379,587...101,442,808
Ensembl chr11:101,379,590...101,442,781
|
|
G |
Brca2 |
breast cancer 2, early onset |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of BRCA2 mRNA [arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA |
CTD |
PMID:21917757 PMID:25913414 |
|
NCBI chr 5:150,445,759...150,493,612
Ensembl chr 5:150,446,095...150,493,794
|
|
G |
Brcc3 |
BRCA1/BRCA2-containing complex, subunit 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of BRCC3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:74,460,234...74,499,307
Ensembl chr X:74,460,234...74,497,607
|
|
G |
Brf2 |
BRF2, RNA polymerase III transcription initiation factor 50kDa subunit |
increases expression |
ISO |
Bortezomib results in increased expression of BRF2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:27,613,367...27,618,743
Ensembl chr 8:27,613,392...27,618,708
|
|
G |
Bsdc1 |
BSD domain containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of BSDC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:129,355,472...129,382,291
Ensembl chr 4:129,355,374...129,382,291
|
|
G |
Caap1 |
caspase activity and apoptosis inhibitor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CAAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:94,388,318...94,445,033
Ensembl chr 4:94,388,318...94,445,033
|
|
G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
decreases degradation |
EXP |
Bortezomib results in decreased degradation of CACNA1H protein |
CTD |
PMID:30552955 |
|
NCBI chr17:25,593,259...25,655,308
Ensembl chr17:25,593,259...25,652,759
|
|
G |
Calr |
calreticulin |
multiple interactions increases expression |
ISO EXP |
[CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein] [Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]] |
CTD |
PMID:30482226 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Capn15 |
calpain 15 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CAPN15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:26,177,338...26,204,753
Ensembl chr17:26,177,338...26,204,770
|
|
G |
Car9 |
carbonic anhydrase 9 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CA9 protein |
CTD |
PMID:16061869 |
|
NCBI chr 4:43,507,026...43,513,729
Ensembl chr 4:43,506,966...43,513,729
|
|
G |
Card9 |
caspase recruitment domain family, member 9 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 2:26,242,199...26,250,957
Ensembl chr 2:26,242,188...26,250,930
|
|
G |
Casp12 |
caspase 12 |
increases cleavage |
EXP |
Bortezomib results in increased cleavage of CASP12 protein |
CTD |
PMID:15509775 PMID:16357177 |
|
NCBI chr 9:5,345,419...5,373,034
Ensembl chr 9:5,345,430...5,373,032
|
|
G |
Casp2 |
caspase 2 |
multiple interactions increases response to substance increases cleavage |
ISO |
benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein] CASP2 results in increased susceptibility to Bortezomib Bortezomib results in increased cleavage of CASP2 protein |
CTD |
PMID:15509775 PMID:16446371 PMID:18723477 |
|
NCBI chr 6:42,241,942...42,259,442
Ensembl chr 6:42,241,919...42,259,442
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased activity of CASP3 protein Bortezomib results in increased cleavage of CASP3 protein Bortezomib results in increased expression of CASP3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [capillarisin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein] |
CTD |
PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:15514602 PMID:15930312 PMID:16024631 PMID:16118318 PMID:16357177 PMID:16617327 PMID:16675587 PMID:16778179 PMID:16904634 PMID:16985072 PMID:17121930 PMID:17156654 PMID:17326159 PMID:17351739 PMID:17495969 PMID:17510429 PMID:17898295 PMID:17898787 PMID:18005386 PMID:18223231 PMID:18223318 PMID:18342500 PMID:18534018 PMID:18641367 PMID:18718063 PMID:18790767 PMID:19100720 PMID:19261616 PMID:19417023 PMID:19662097 PMID:20022965 PMID:20051518 PMID:20150630 PMID:20383943 PMID:20471514 PMID:20524303 PMID:20850924 PMID:21195056 PMID:21345073 PMID:21472287 PMID:21518486 PMID:22262760 PMID:22842577 PMID:23063726 PMID:23300809 PMID:24291039 PMID:24333736 PMID:24377552 PMID:29384525 PMID:30482226 PMID:31540997 PMID:33775688 More...
|
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp4 |
caspase 4, apoptosis-related cysteine peptidase |
multiple interactions increases response to substance increases cleavage increases activity |
ISO |
[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] CASP4 protein results in increased susceptibility to Bortezomib Bortezomib results in increased activity of CASP4 protein |
CTD |
PMID:16357177 PMID:18641367 |
|
NCBI chr 9:5,308,816...5,336,791
Ensembl chr 9:5,308,828...5,336,783
|
|
G |
Casp6 |
caspase 6 |
multiple interactions increases cleavage |
ISO |
Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] |
CTD |
PMID:16617327 PMID:17510429 |
|
NCBI chr 3:129,695,064...129,707,761
Ensembl chr 3:129,695,074...129,707,752
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases cleavage increases activity |
ISO |
[Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein] Bortezomib results in increased activity of CASP7 protein |
CTD |
PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 PMID:20022965 PMID:20524303 PMID:23300809 PMID:31540997 More...
|
|
NCBI chr19:56,382,640...56,430,780
Ensembl chr19:56,385,561...56,430,776
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; ricolinostat promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] |
CTD |
PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 PMID:15930312 PMID:16024631 PMID:16118318 PMID:16617327 PMID:16778179 PMID:16904634 PMID:17172406 PMID:17326159 PMID:17351739 PMID:17510429 PMID:17620439 PMID:17626072 PMID:17659339 PMID:17898787 PMID:18005386 PMID:18641367 PMID:19100720 PMID:19261616 PMID:19417023 PMID:20051518 PMID:20442297 PMID:20471514 PMID:21345073 PMID:22262760 PMID:24291039 PMID:24377552 PMID:31540997 More...
|
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases response to substance increases cleavage |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [ricolinostat co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein] Bortezomib results in increased expression of CASP9 protein CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib |
CTD |
PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 PMID:16118318 PMID:16617327 PMID:16778179 PMID:16904634 PMID:16985072 PMID:17156654 PMID:17326159 PMID:17510429 PMID:17620439 PMID:17626072 PMID:17898295 PMID:17898787 PMID:18005386 PMID:18223231 PMID:18641367 PMID:18723477 PMID:19261616 PMID:19417023 PMID:20051518 PMID:20471514 PMID:20850924 PMID:20864405 PMID:21345073 PMID:21518486 PMID:22262760 PMID:24291039 PMID:24377552 PMID:31540997 More...
|
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of CAT protein Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein] |
CTD |
PMID:35121005 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cbl |
Casitas B-lineage lymphoma |
multiple interactions |
ISO |
[Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] |
CTD |
PMID:19457607 |
|
NCBI chr 9:44,054,273...44,145,556
Ensembl chr 9:44,054,273...44,145,346
|
|
G |
Cbr3 |
carbonyl reductase 3 |
increases expression |
ISO |
[Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA |
CTD |
PMID:20806931 PMID:20977926 |
|
NCBI chr16:93,480,107...93,487,879
Ensembl chr16:93,480,103...93,487,878
|
|
G |
Cbx3 |
chromobox 3 |
increases expression |
ISO |
Bortezomib results in increased expression of CBX3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:51,447,596...51,460,684
Ensembl chr 6:51,447,340...51,460,684
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CCAR1 protein |
CTD |
PMID:21594647 PMID:21903591 |
|
NCBI chr10:62,579,707...62,628,147
Ensembl chr10:62,579,707...62,628,065
|
|
G |
Ccdc186 |
coiled-coil domain containing 186 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC186 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:56,775,917...56,810,631
Ensembl chr19:56,775,913...56,810,622
|
|
G |
Ccdc32 |
coiled-coil domain containing 32 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC32 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:118,848,260...118,859,887
Ensembl chr 2:118,848,260...118,859,874
|
|
G |
Ccdc6 |
coiled-coil domain containing 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCDC6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:69,932,709...70,029,030
Ensembl chr10:69,932,951...70,029,030
|
|
G |
Ccdc82 |
coiled-coil domain containing 82 |
increases expression |
ISO |
Bortezomib results in increased expression of CCDC82 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:13,246,573...13,292,867
Ensembl chr 9:13,246,536...13,292,867
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCL2 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression decreases expression |
ISO EXP |
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein Bortezomib results in decreased expression of CCL3 mRNA |
CTD |
PMID:18089816 PMID:20830808 |
|
NCBI chr11:83,538,669...83,540,204
Ensembl chr11:83,538,670...83,540,181
|
|
G |
Ccl8 |
C-C motif chemokine ligand 8 |
affects expression |
ISO |
Bortezomib affects the expression of CCL8 protein |
CTD |
PMID:19922463 |
|
NCBI chr11:82,006,011...82,007,625
Ensembl chr11:82,006,011...82,007,625
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein Bortezomib results in increased expression of CCNB1 protein |
CTD |
PMID:19074855 PMID:20367638 PMID:25522274 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with Vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Vorinostat] results in decreased expression of CCND1 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of CCND1 protein] |
CTD |
PMID:12893773 PMID:15173093 PMID:15781649 PMID:24333736 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CCND2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Ccnf |
cyclin F |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA |
CTD |
PMID:25522274 |
|
NCBI chr17:24,441,518...24,470,333
Ensembl chr17:24,441,172...24,470,458
|
|
G |
Ccng2 |
cyclin G2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 5:93,415,432...93,424,090
Ensembl chr 5:93,415,116...93,424,090
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CCPG1 mRNA |
CTD |
PMID:20471514 PMID:20977926 |
|
NCBI chr 9:72,892,692...72,923,622
Ensembl chr 9:72,892,711...72,923,622
|
|
G |
Cd27 |
CD27 antigen |
increases expression |
ISO |
Bortezomib results in increased expression of CD27 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 6:125,209,583...125,214,014
Ensembl chr 6:125,209,585...125,213,973
|
|
G |
Cd38 |
CD38 antigen |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD38 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:44,026,153...44,069,714
Ensembl chr 5:44,025,895...44,069,717
|
|
G |
Cd5 |
CD5 antigen |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:10,695,471...10,716,390
Ensembl chr19:10,694,480...10,716,366
|
|
G |
Cd69 |
CD69 antigen |
increases expression |
ISO |
Bortezomib results in increased expression of CD69 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:129,244,287...129,252,332
Ensembl chr 6:129,244,288...129,252,399
|
|
G |
Cd79a |
CD79A antigen (immunoglobulin-associated alpha) |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD79A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:24,596,922...24,601,283
Ensembl chr 7:24,596,806...24,601,622
|
|
G |
Cd82 |
CD82 antigen |
decreases expression |
ISO |
Bortezomib results in decreased expression of CD82 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:93,249,447...93,293,295
Ensembl chr 2:93,249,456...93,293,485
|
|
G |
Cd9 |
CD9 antigen |
increases expression |
ISO |
Bortezomib results in increased expression of CD9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:125,437,229...125,471,723
Ensembl chr 6:125,437,229...125,471,754
|
|
G |
Cdc23 |
CDC23 cell division cycle 23 |
increases expression |
ISO |
Bortezomib results in increased expression of CDC23 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:34,761,401...34,784,802
Ensembl chr18:34,764,004...34,784,788
|
|
G |
Cdc34 |
cell division cycle 34 |
increases expression |
ISO |
Bortezomib results in increased expression of CDC34 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:79,518,029...79,524,232
Ensembl chr10:79,518,029...79,524,232
|
|
G |
Cdc37 |
cell division cycle 37 |
increases expression |
ISO |
Bortezomib results in increased expression of CDC37 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:21,050,727...21,061,230
Ensembl chr 9:21,044,518...21,061,278
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDC42 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:137,047,011...137,085,007
Ensembl chr 4:137,047,007...137,085,031
|
|
G |
Cdc42se2 |
CDC42 small effector 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDC42SE2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:54,608,241...54,678,549
Ensembl chr11:54,608,282...54,678,501
|
|
G |
Cdk1 |
cyclin dependent kinase 1 |
multiple interactions increases phosphorylation increases activity decreases activity |
ISO |
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein] Bortezomib results in increased phosphorylation of CDK1 protein Bortezomib results in increased activity of CDK1 protein Bortezomib results in decreased activity of CDK1 protein |
CTD |
PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 |
|
NCBI chr10:69,170,976...69,188,742
Ensembl chr10:69,170,976...69,188,768
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
ISO |
Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein] Bortezomib results in decreased activity of CDK2 protein |
CTD |
PMID:14749476 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases stability multiple interactions decreases response to substance increases expression |
ISO |
Bortezomib results in increased stability of CDKN1A protein [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel] CDKN1A results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein |
CTD |
PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 PMID:15930312 PMID:16928825 PMID:17327374 PMID:17898295 PMID:18223318 PMID:18445700 PMID:18790767 PMID:19220424 PMID:19417023 PMID:20383943 PMID:20977926 PMID:21345073 PMID:36401358 More...
|
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions increases stability increases expression |
ISO |
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1B protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein] Bortezomib results in increased stability of CDKN1B protein |
CTD |
PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 PMID:18850583 PMID:19220424 PMID:19636294 PMID:20701607 More...
|
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CDT1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 8:123,294,754...123,299,869
Ensembl chr 8:123,294,754...123,300,293
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] |
CTD |
PMID:19662097 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions decreases expression increases expression |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form] Bortezomib results in decreased expression of CEBPB mRNA 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] |
CTD |
PMID:20471514 PMID:20830808 PMID:30482226 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Cenpc1 |
centromere protein C1 |
increases expression |
ISO |
Bortezomib results in increased expression of CENPC mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:86,159,877...86,214,325
Ensembl chr 5:86,159,883...86,213,442
|
|
G |
Cep290 |
centrosomal protein 290 |
increases expression |
ISO |
Bortezomib results in increased expression of CEP290 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:100,323,410...100,409,527
Ensembl chr10:100,323,420...100,410,702
|
|
G |
Cers2 |
ceramide synthase 2 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [CERS2 protein affects the expression of ABCB1 protein] |
CTD |
PMID:34915026 |
|
NCBI chr 3:95,222,077...95,230,910
Ensembl chr 3:95,222,102...95,230,910
|
|
G |
Cers6 |
ceramide synthase 6 |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [CERS6 protein affects the expression of ABCB1 protein] |
CTD |
PMID:34915026 |
|
NCBI chr 2:68,691,489...68,944,628
Ensembl chr 2:68,691,785...68,944,626
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions decreases response to substance decreases expression increases expression |
ISO |
Bortezomib affects the expression of CFLAR protein [Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein] CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form |
CTD |
PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 PMID:18223231 PMID:19100720 PMID:19922463 PMID:20515944 PMID:20876774 More...
|
|
NCBI chr 1:58,750,353...58,798,043
Ensembl chr 1:58,750,667...58,798,043
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CGREF1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 5:31,090,487...31,102,771
Ensembl chr 5:31,090,487...31,102,935
|
|
G |
Chac1 |
ChaC, cation transport regulator 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CHAC1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 2:119,181,723...119,184,807
Ensembl chr 2:119,181,710...119,184,862
|
|
G |
Chaf1a |
chromatin assembly factor 1, subunit A |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHAF1A mRNA |
CTD |
PMID:17659339 |
|
NCBI chr17:56,347,404...56,375,027
Ensembl chr17:56,347,439...56,379,289
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of CHD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:73,076,400...73,191,494
Ensembl chr 7:73,076,386...73,191,578
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHFR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:110,283,599...110,319,839
Ensembl chr 5:110,283,708...110,319,838
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHST11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:82,820,274...83,031,738
Ensembl chr10:82,821,332...83,031,734
|
|
G |
Chst2 |
carbohydrate sulfotransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CHST2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:95,282,979...95,289,323
Ensembl chr 9:95,281,345...95,288,775
|
|
G |
Chuk |
conserved helix-loop-helix ubiquitous kinase |
increases expression increases activity |
ISO |
Bortezomib results in increased expression of CHUK mRNA Bortezomib results in increased activity of CHUK protein |
CTD |
PMID:20471514 PMID:24085292 |
|
NCBI chr19:44,061,773...44,095,940
Ensembl chr19:44,061,774...44,095,919
|
|
G |
Cideb |
cell death-inducing DNA fragmentation factor, alpha subunit-like effector B |
decreases expression |
ISO |
Bortezomib results in decreased expression of CIDEB mRNA |
CTD |
PMID:17659339 |
|
NCBI chr14:55,991,509...55,995,881
Ensembl chr14:55,991,507...55,995,915
|
|
G |
Cilk1 |
ciliogenesis associated kinase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CILK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:78,016,425...78,079,396
Ensembl chr 9:78,016,474...78,079,389
|
|
G |
Clec7a |
C-type lectin domain family 7, member a |
increases expression |
ISO |
Bortezomib results in increased expression of CLEC7A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:129,438,554...129,449,748
Ensembl chr 6:129,438,554...129,449,742
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
increases expression |
ISO |
Bortezomib results in increased expression of CLIP4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:72,076,674...72,171,205
Ensembl chr17:72,075,468...72,171,268
|
|
G |
Cln6 |
ceroid-lipofuscinosis, neuronal 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CLN6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:62,746,067...62,759,288
Ensembl chr 9:62,746,067...62,759,288
|
|
G |
Clptm1 |
cleft lip and palate associated transmembrane protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CLPTM1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:19,365,505...19,398,955
Ensembl chr 7:19,365,496...19,398,958
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Bortezomib results in increased expression of CLU mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:66,206,093...66,218,992
Ensembl chr14:66,205,932...66,218,996
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
decreases expression |
ISO |
Bortezomib results in decreased expression of COX8A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr19:7,192,523...7,194,981
Ensembl chr19:7,192,518...7,194,981
|
|
G |
Cpt1c |
carnitine palmitoyltransferase 1c |
increases response to substance |
ISO |
CPT1C gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 7:44,607,907...44,624,304
Ensembl chr 7:44,608,796...44,624,275
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crebbp |
CREB binding protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of CREBBP mRNA |
CTD |
PMID:25913414 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
ISO |
Bortezomib results in increased expression of CREM mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:3,263,181...3,337,688
Ensembl chr18:3,266,048...3,337,748
|
|
G |
Crip2 |
cysteine rich protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CRIP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:113,103,856...113,109,126
Ensembl chr12:113,103,856...113,109,126
|
|
G |
Cripto |
cripto, EGF-CFC family member |
increases expression |
ISO |
Bortezomib results in increased expression of CRIPTO mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 9:110,768,676...110,775,226
Ensembl chr 9:110,768,671...110,775,226
|
|
G |
Crkl |
v-crk avian sarcoma virus CT10 oncogene homolog-like |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein |
CTD |
PMID:15039284 |
|
NCBI chr16:17,269,849...17,305,304
Ensembl chr16:17,269,851...17,305,298
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions increases expression |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA Bortezomib results in increased expression of CRYAB mRNA |
CTD |
PMID:20830808 PMID:25522274 |
|
NCBI chr 9:50,657,251...50,667,936
Ensembl chr 9:50,662,625...50,667,936
|
|
G |
Cst7 |
cystatin F (leukocystatin) |
increases expression |
ISO |
Bortezomib results in increased expression of CST7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:150,412,335...150,420,864
Ensembl chr 2:150,412,335...150,420,864
|
|
G |
Ctdspl2 |
CTD small phosphatase like 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CTDSPL2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:121,785,879...121,845,807
Ensembl chr 2:121,786,482...121,844,123
|
|
G |
Cth |
cystathionine gamma lyase |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases response to substance increases expression |
ISO |
2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] |
CTD |
PMID:18485479 PMID:19100720 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsb |
cathepsin B |
multiple interactions increases localization |
ISO |
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] |
CTD |
PMID:16446371 |
|
NCBI chr14:63,359,911...63,383,372
Ensembl chr14:63,359,911...63,383,372
|
|
G |
Ctsd |
cathepsin D |
increases expression |
ISO |
Bortezomib results in increased expression of CTSD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Cul1 |
cullin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CUL1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 6:47,430,516...47,503,078
Ensembl chr 6:47,430,332...47,503,073
|
|
G |
Cul3 |
cullin 3 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CUL3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 1:80,242,640...80,318,426
Ensembl chr 1:80,242,640...80,318,197
|
|
G |
Cwf19l1 |
CWF19 like cell cycle control factor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CWF19L1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:44,097,076...44,124,324
Ensembl chr19:44,097,076...44,124,315
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CXCL1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
increases expression multiple interactions increases secretion |
ISO |
Bortezomib results in increased expression of CXCL8 mRNA Bortezomib inhibits the reaction [Vorinostat results in increased expression of CXCL8 mRNA]; SC 514 inhibits the reaction [Bortezomib results in increased secretion of CXCL8 protein] |
CTD |
PMID:15509775 PMID:15514602 PMID:17172406 PMID:24085292 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
EXP ISO |
Bortezomib results in increased expression of CXCL2 mRNA Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA] |
CTD |
PMID:20830808 PMID:27194111 |
|
NCBI chr 5:91,051,758...91,053,797
Ensembl chr 5:91,051,730...91,053,797
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression |
EXP ISO |
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA] Bortezomib results in increased expression of CXCL1 mRNA |
CTD |
PMID:15509775 PMID:27194111 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of CXCR4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:128,515,936...128,520,036
Ensembl chr 1:128,515,936...128,520,030
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CYB5R1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:134,333,519...134,339,476
Ensembl chr 1:134,333,297...134,339,478
|
|
G |
Cyba |
cytochrome b-245, alpha polypeptide |
decreases expression |
ISO |
Bortezomib results in decreased expression of CYBA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:123,151,510...123,159,679
Ensembl chr 8:123,151,515...123,159,669
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
[Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein Bortezomib affects the localization of CYCS protein |
CTD |
PMID:12893773 PMID:16024631 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing |
ISO |
CYP1A2 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp2c38 |
cytochrome P450, family 2, subfamily c, polypeptide 38 |
affects metabolic processing |
ISO |
CYP2C19 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr19:39,379,109...39,451,519
Ensembl chr19:39,378,000...39,451,519
|
|
G |
Cyp2c65 |
cytochrome P450, family 2, subfamily c, polypeptide 65 |
affects metabolic processing |
ISO |
CYP2C9 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr19:39,049,450...39,082,392
Ensembl chr19:39,049,459...39,082,388
|
|
G |
Cyp2d22 |
cytochrome P450, family 2, subfamily d, polypeptide 22 |
affects metabolic processing |
ISO |
CYP2D6 protein affects the metabolism of Bortezomib |
CTD |
PMID:15764713 |
|
NCBI chr15:82,254,728...82,264,461
Ensembl chr15:82,254,728...82,264,461
|
|
G |
Cyp2u1 |
cytochrome P450, family 2, subfamily u, polypeptide 1 |
increases expression |
ISO |
Bortezomib results in increased expression of CYP2U1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:131,084,140...131,097,806
Ensembl chr 3:131,082,090...131,096,876
|
|
G |
Cytip |
cytohesin 1 interacting protein |
increases expression |
ISO |
Bortezomib results in increased expression of CYTIP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:58,019,151...58,085,559
Ensembl chr 2:58,019,149...58,085,544
|
|
G |
D430019H16Rik |
RIKEN cDNA D430019H16 gene |
decreases expression |
ISO |
Bortezomib results in decreased expression of C14ORF132 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:105,420,115...105,459,354
Ensembl chr12:105,420,115...105,459,354
|
|
G |
Dap3 |
death associated protein 3 |
increases expression |
ISO |
Bortezomib results in increased expression of DAP3 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 3:88,828,110...88,858,504
Ensembl chr 3:88,828,110...88,858,488
|
|
G |
Dapk2 |
death-associated protein kinase 2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 9:66,065,364...66,179,524
Ensembl chr 9:66,065,505...66,179,524
|
|
G |
Dazap2 |
DAZ associated protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DAZAP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:100,513,543...100,518,642
Ensembl chr15:100,513,230...100,518,642
|
|
G |
Dbn1 |
drebrin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of DBN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:55,621,241...55,635,874
Ensembl chr13:55,621,242...55,635,924
|
|
G |
Dcaf11 |
DDB1 and CUL4 associated factor 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DCAF11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:55,796,557...55,807,522
Ensembl chr14:55,797,463...55,807,522
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
increases expression |
ISO |
Bortezomib results in increased expression of DCAF13 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:38,976,300...39,010,251
Ensembl chr15:38,976,260...39,010,251
|
|
G |
Dcps |
decapping enzyme, scavenger |
decreases expression |
ISO |
Bortezomib results in decreased expression of DCPS mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:35,035,710...35,087,283
Ensembl chr 9:35,035,704...35,087,357
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein] Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Betulinic Acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein] DDIT3 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 PMID:17898295 PMID:18723477 PMID:20022965 PMID:20110775 PMID:20830808 PMID:22959925 PMID:24291039 PMID:30482226 More...
|
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddx11 |
DEAD/H box helicase 11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DDX11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:66,430,508...66,459,169
Ensembl chr17:66,430,515...66,459,169
|
|
G |
Deaf1 |
DEAF1, transcription factor |
decreases expression |
ISO |
Bortezomib results in decreased expression of DEAF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:140,877,089...140,918,758
Ensembl chr 7:140,877,093...140,907,603
|
|
G |
Dedd2 |
death effector domain-containing DNA binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of DEDD2 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 7:24,899,337...24,920,035
Ensembl chr 7:24,899,340...24,920,040
|
|
G |
Def6 |
differentially expressed in FDCP 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DEF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:28,426,752...28,447,582
Ensembl chr17:28,426,752...28,447,582
|
|
G |
Dennd4a |
DENN domain containing 4A |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:64,713,408...64,826,949
Ensembl chr 9:64,718,622...64,826,949
|
|
G |
Dennd4b |
DENN domain containing 4B |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4B mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 3:90,172,281...90,187,972
Ensembl chr 3:90,172,492...90,187,976
|
|
G |
Dennd4c |
DENN domain containing 4C |
increases expression |
ISO |
Bortezomib results in increased expression of DENND4C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:86,666,761...86,768,841
Ensembl chr 4:86,666,792...86,768,840
|
|
G |
Dgke |
diacylglycerol kinase, epsilon |
decreases expression |
ISO |
Bortezomib results in decreased expression of DGKE mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:88,926,005...88,951,644
Ensembl chr11:88,926,005...88,957,676
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization increases localization increases expression multiple interactions |
ISO |
Bortezomib affects the localization of DIABLO protein Bortezomib results in increased localization of DIABLO protein Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein] |
CTD |
PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 PMID:16024631 PMID:17327374 PMID:25913414 More...
|
|
NCBI chr 5:123,649,393...123,664,825
Ensembl chr 5:123,647,828...123,662,239
|
|
G |
Dlgap5 |
DLG associated protein 5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr14:47,625,238...47,655,657
Ensembl chr14:47,625,236...47,655,864
|
|
G |
Dnaaf5 |
dynein, axonemal assembly factor 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAAF5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:139,135,888...139,172,265
Ensembl chr 5:139,135,978...139,172,265
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
Bortezomib results in increased expression of DNAJB1 mRNA |
CTD |
PMID:15509775 |
|
NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
|
|
G |
Dnajc14 |
DnaJ heat shock protein family (Hsp40) member C14 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAJC14 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:128,641,423...128,655,317
Ensembl chr10:128,639,931...128,655,315
|
|
G |
Dnajc4 |
DnaJ heat shock protein family (Hsp40) member C4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNAJC4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:6,965,279...6,969,954
Ensembl chr19:6,965,279...6,969,940
|
|
G |
Dnm2 |
dynamin 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DNM2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:21,336,167...21,419,055
Ensembl chr 9:21,336,204...21,419,055
|
|
G |
Dpy19l4 |
dpy-19 like 4 |
increases expression |
ISO |
Bortezomib results in increased expression of DPY19L4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:11,261,315...11,322,153
Ensembl chr 4:11,261,315...11,322,137
|
|
G |
Dst |
dystonin |
increases expression |
ISO |
Bortezomib results in increased expression of DST mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 1:33,946,969...34,347,743
Ensembl chr 1:33,947,306...34,347,742
|
|
G |
Dusp15 |
dual specificity phosphatase-like 15 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DUSP15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:152,782,915...152,794,200
Ensembl chr 2:152,782,917...152,793,618
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of DUSP4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:35,274,448...35,289,106
Ensembl chr 8:35,274,451...35,287,048
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr19:53,517,576...53,530,240
Ensembl chr19:53,517,540...53,530,862
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
increases expression |
ISO |
Bortezomib results in increased expression of DYNC1I1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:5,725,772...6,028,030
Ensembl chr 6:5,725,639...6,028,039
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein |
CTD |
PMID:25522274 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
increases expression |
ISO |
Bortezomib results in increased expression of ECPAS mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:58,797,234...58,917,748
Ensembl chr 4:58,798,911...58,912,749
|
|
G |
Edaradd |
EDAR associated via death domain |
increases expression |
ISO |
Bortezomib results in increased expression of EDARADD mRNA |
CTD |
PMID:17895889 |
|
NCBI chr13:12,486,090...12,535,413
Ensembl chr13:12,487,513...12,535,319
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr12:54,225,767...54,250,660
Ensembl chr12:54,225,767...54,250,646
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Bortezomib results in increased expression of EGR1 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr18:34,994,260...34,998,009
Ensembl chr18:34,992,876...34,998,037
|
|
G |
Egr2 |
early growth response 2 |
decreases expression |
EXP ISO |
Bortezomib results in decreased expression of EGR2 mRNA Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein |
CTD |
PMID:20830808 |
|
NCBI chr10:67,370,334...67,383,354
Ensembl chr10:67,371,305...67,378,018
|
|
G |
Ehmt2 |
euchromatic histone lysine N-methyltransferase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EHMT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:35,117,427...35,133,049
Ensembl chr17:35,117,445...35,133,028
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of EIF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:100,210,775...100,212,925
Ensembl chr11:100,210,711...100,212,922
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
decreases phosphorylation |
ISO |
Bortezomib results in decreased phosphorylation of EIF2A protein |
CTD |
PMID:18641367 |
|
NCBI chr 3:58,433,252...58,464,922
Ensembl chr 3:58,433,242...58,464,922
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation multiple interactions decreases response to substance |
ISO EXP |
Bortezomib results in increased phosphorylation of EIF2AK3 protein Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]] Bortezomib promotes the reaction [ricolinostat results in increased phosphorylation of EIF2AK3 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:16928686 PMID:20022965 PMID:22262760 PMID:22959925 |
|
NCBI chr 6:70,821,468...70,882,225
Ensembl chr 6:70,821,499...70,882,229
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
multiple interactions increases phosphorylation |
ISO EXP |
Bortezomib affects the reaction [ricolinostat results in increased phosphorylation of EIF2S1 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:16357177 PMID:20022965 PMID:21090173 PMID:22262760 |
|
NCBI chr12:78,908,846...78,933,784
Ensembl chr12:78,908,593...78,933,784
|
|
G |
Eif2s3x |
eukaryotic translation initiation factor 2, subunit 3, structural gene X-linked |
decreases expression |
ISO |
Bortezomib results in decreased expression of EIF2S3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:93,232,315...93,256,257
Ensembl chr X:93,232,313...93,256,468
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:21345073 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Bortezomib results in decreased expression of EIF5A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:69,807,538...69,812,784
Ensembl chr11:69,807,540...69,812,784
|
|
G |
Elp5 |
elongator acetyltransferase complex subunit 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ELP5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:69,859,050...69,872,352
Ensembl chr11:69,859,048...69,873,343
|
|
G |
Eno2 |
enolase 2, gamma neuronal |
increases expression |
ISO |
Bortezomib results in increased expression of ENO2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:124,737,018...124,746,489
Ensembl chr 6:124,737,016...124,746,636
|
|
G |
Epha1 |
Eph receptor A1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EPHA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:42,335,421...42,350,249
Ensembl chr 6:42,335,421...42,350,202
|
|
G |
Ephb2 |
Eph receptor B2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of EPHB2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:136,374,850...136,563,637
Ensembl chr 4:136,374,850...136,563,299
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases phosphorylation |
ISO |
Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] |
CTD |
PMID:20701607 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Ercc3 |
excision repair cross-complementing rodent repair deficiency, complementation group 3 |
increases response to substance |
ISO |
ERCC3 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr18:32,373,357...32,403,206
Ensembl chr18:32,373,353...32,403,204
|
|
G |
Ercc4 |
excision repair cross-complementing rodent repair deficiency, complementation group 4 |
increases response to substance |
ISO |
ERCC4 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr16:12,927,600...12,969,873
Ensembl chr16:12,927,548...12,968,481
|
|
G |
Erlin2 |
ER lipid raft associated 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ERLIN2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:27,513,399...27,529,465
Ensembl chr 8:27,513,289...27,530,356
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signalling 1 |
multiple interactions decreases response to substance |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; Bortezomib affects the reaction [ricolinostat affects the phosphorylation of ERN1 protein] ERN1 results in decreased susceptibility to Bortezomib |
CTD |
PMID:16357177 PMID:22262760 PMID:25522274 |
|
NCBI chr11:106,285,474...106,378,701
Ensembl chr11:106,285,476...106,378,678
|
|
G |
Esf1 |
ESF1 nucleolar pre-rRNA processing protein homolog |
increases expression |
ISO |
Bortezomib results in increased expression of ESF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:139,961,800...140,012,498
Ensembl chr 2:139,961,803...140,012,484
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:25752796 PMID:30818834 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esr2 |
estrogen receptor 2 (beta) |
multiple interactions |
ISO |
[Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] |
CTD |
PMID:25752796 PMID:25913414 PMID:30818834 |
|
NCBI chr12:76,167,193...76,224,033
Ensembl chr12:76,167,193...76,224,033
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of ESRRA mRNA Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:20977926 PMID:30818834 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Esyt2 |
extended synaptotagmin-like protein 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ESYT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:116,242,903...116,354,555
Ensembl chr12:116,244,816...116,354,670
|
|
G |
Etv4 |
ets variant 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ETV4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:101,660,573...101,677,963
Ensembl chr11:101,660,568...101,676,197
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of F2RL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:95,648,226...95,661,748
Ensembl chr13:95,648,240...95,661,735
|
|
G |
F3 |
coagulation factor III |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of F3 protein [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein |
CTD |
PMID:23696885 |
|
NCBI chr 3:121,517,186...121,528,701
Ensembl chr 3:121,517,186...121,528,697
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FADS2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:10,040,129...10,078,867
Ensembl chr19:10,040,129...10,079,110
|
|
G |
Faf1 |
Fas-associated factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of FAF1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 4:109,533,873...109,821,157
Ensembl chr 4:109,533,785...109,821,157
|
|
G |
Fam118b |
family with sequence similarity 118, member B |
increases expression |
ISO |
Bortezomib results in increased expression of FAM118B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:35,128,261...35,179,172
Ensembl chr 9:35,128,261...35,179,101
|
|
G |
Fam168a |
family with sequence similarity 168, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM168A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:100,355,594...100,490,853
Ensembl chr 7:100,355,842...100,490,863
|
|
G |
Fam20b |
FAM20B, glycosaminoglycan xylosylkinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of FAM20B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:156,506,127...156,547,204
Ensembl chr 1:156,506,102...156,546,656
|
|
G |
Fam219a |
family with sequence similarity 219, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM219A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:41,517,691...41,569,538
Ensembl chr 4:41,517,691...41,569,538
|
|
G |
Fam241b |
family with sequence similarity 241, member B |
increases expression |
ISO |
Bortezomib results in increased expression of FAM241B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:61,943,435...61,946,829
Ensembl chr10:61,943,434...61,979,699
|
|
G |
Fam43a |
family with sequence similarity 43, member A |
decreases expression |
ISO |
Bortezomib results in decreased expression of FAM43A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:30,418,541...30,421,615
Ensembl chr16:30,418,541...30,421,615
|
|
G |
Fam76a |
family with sequence similarity 76, member A |
increases expression |
ISO |
Bortezomib results in increased expression of FAM76A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:132,626,524...132,649,849
Ensembl chr 4:132,626,524...132,649,869
|
|
G |
Fancd2 |
Fanconi anemia, complementation group D2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein |
CTD |
PMID:19934314 PMID:21917757 |
|
NCBI chr 6:113,508,622...113,573,981
Ensembl chr 6:113,508,643...113,573,978
|
|
G |
Farsa |
phenylalanyl-tRNA synthetase, alpha subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of FARSA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:85,583,597...85,595,886
Ensembl chr 8:85,583,618...85,595,886
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions decreases expression increases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in increased expression of FAS protein Bortezomib results in decreased expression of FAS mRNA Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein |
CTD |
PMID:17351739 PMID:20471514 PMID:25913414 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
multiple interactions increases expression |
ISO |
[Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein] Bortezomib results in increased expression of FASLG protein |
CTD |
PMID:17351739 PMID:20471514 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
Bortezomib results in decreased expression of FASTK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:24,646,036...24,650,280
Ensembl chr 5:24,643,438...24,650,285
|
|
G |
Fbln5 |
fibulin 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FBLN5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:101,712,820...101,785,541
Ensembl chr12:101,712,824...101,785,314
|
|
G |
Fbxw7 |
F-box and WD-40 domain protein 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FBXW7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:84,721,901...84,886,505
Ensembl chr 3:84,722,575...84,886,505
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 7:45,263,314...45,264,914
Ensembl chr 7:45,263,310...45,264,914
|
|
G |
Fgfr1op2 |
FGFR1 oncogene partner 2 |
increases expression |
ISO |
Bortezomib results in increased expression of FGFR1OP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:146,479,401...146,500,696
Ensembl chr 6:146,478,701...146,500,696
|
|
G |
Fkbp1a |
FK506 binding protein 1a |
decreases expression |
ISO |
Bortezomib results in decreased expression of FKBP1A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:151,384,403...151,403,611
Ensembl chr 2:151,384,403...151,403,612
|
|
G |
Fkbp5 |
FK506 binding protein 5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FKBP5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:28,617,727...28,705,123
Ensembl chr17:28,618,068...28,736,501
|
|
G |
Flcn |
folliculin |
increases expression |
ISO |
Bortezomib results in increased expression of FLCN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:59,682,234...59,706,138
Ensembl chr11:59,682,234...59,700,842
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of FMR1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr X:67,722,144...67,761,569
Ensembl chr X:67,722,147...67,761,569
|
|
G |
Folr1 |
folate receptor alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of FOLR1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:101,507,551...101,519,974
Ensembl chr 7:101,507,538...101,519,995
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA Bortezomib results in decreased expression of FOXA1 mRNA |
CTD |
PMID:20471514 PMID:25913414 |
|
NCBI chr12:57,585,750...57,594,815
Ensembl chr12:57,587,414...57,593,702
|
|
G |
Fry |
FRY microtubule binding protein |
increases expression |
ISO |
Bortezomib results in increased expression of FRY mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:150,042,083...150,421,218
Ensembl chr 5:150,042,110...150,421,218
|
|
G |
Fsd1l |
fibronectin type III and SPRY domain containing 1-like |
increases expression |
ISO |
Bortezomib results in increased expression of FSD1L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:53,631,383...53,707,009
Ensembl chr 4:53,631,471...53,707,009
|
|
G |
Fzd2 |
frizzled class receptor 2 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr11:102,495,257...102,498,884
Ensembl chr11:102,495,222...102,498,884
|
|
G |
G6pdx |
glucose-6-phosphate dehydrogenase X-linked |
decreases expression |
ISO |
Bortezomib results in decreased expression of G6PD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:73,453,089...73,472,486
Ensembl chr X:73,453,089...73,472,800
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:129,510,155...129,519,294
Ensembl chr 6:129,510,123...129,519,309
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible 45 alpha |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GADD45A mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA |
CTD |
PMID:20830808 PMID:20977926 PMID:25522274 |
|
NCBI chr 6:67,012,080...67,014,391
Ensembl chr 6:67,012,080...67,014,441
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible 45 beta |
increases expression multiple interactions |
ISO EXP |
Bortezomib results in increased expression of GADD45B mRNA Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA] |
CTD |
PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 |
|
NCBI chr10:80,765,925...80,768,038
Ensembl chr10:80,765,907...80,768,038
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible 45 gamma |
increases expression |
ISO |
Bortezomib results in increased expression of GADD45G mRNA |
CTD |
PMID:17898295 |
|
NCBI chr13:52,000,711...52,002,511
Ensembl chr13:52,000,714...52,002,504
|
|
G |
Galnt4 |
polypeptide N-acetylgalactosaminyltransferase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of GALNT4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:98,943,997...98,949,109
Ensembl chr10:98,944,021...98,949,109
|
|
G |
Ganab |
alpha glucosidase 2 alpha neutral subunit |
decreases expression |
ISO |
Bortezomib results in decreased expression of GANAB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:8,875,440...8,894,098
Ensembl chr19:8,875,435...8,894,036
|
|
G |
Gas7 |
growth arrest specific 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GAS7 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:67,344,083...67,579,818
Ensembl chr11:67,345,917...67,575,800
|
|
G |
Gbp2 |
guanylate binding protein 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GBP2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:142,326,424...142,343,769
Ensembl chr 3:142,326,363...142,343,769
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GCLC mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GCLM mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 (I blood group) |
increases expression |
ISO |
Bortezomib results in increased expression of GCNT2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:41,013,417...41,114,368
Ensembl chr13:41,013,230...41,114,368
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GDF15 mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA |
CTD |
PMID:20830808 PMID:25522274 |
|
NCBI chr 8:71,082,043...71,085,106
Ensembl chr 8:71,082,043...71,085,106
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GFAP mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Ghr |
growth hormone receptor |
increases expression |
ISO |
Bortezomib results in increased expression of GHR mRNA |
CTD |
PMID:17895889 |
|
NCBI chr15:3,347,237...3,612,834
Ensembl chr15:3,347,242...3,612,974
|
|
G |
Git1 |
GIT ArfGAP 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:77,384,114...77,398,600
Ensembl chr11:77,384,388...77,398,612
|
|
G |
Gkap1 |
G kinase anchoring protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:58,381,160...58,422,691
Ensembl chr13:58,381,160...58,423,513
|
|
G |
Gla |
galactosidase, alpha |
increases expression |
ISO |
Bortezomib results in increased expression of GLA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:133,488,912...133,501,707
Ensembl chr X:133,488,898...133,501,874
|
|
G |
Glb1 |
galactosidase, beta 1 |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of GLB1 protein TERT protein inhibits the reaction [Bortezomib results in increased expression of GLB1 protein] |
CTD |
PMID:36401358 |
|
NCBI chr 9:114,230,146...114,303,447
Ensembl chr 9:114,230,144...114,303,966
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases expression |
ISO |
Bortezomib results in increased expression of GNAI3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:108,014,591...108,053,468
Ensembl chr 3:108,014,596...108,053,462
|
|
G |
Gosr2 |
golgi SNAP receptor complex member 2 |
increases expression |
ISO |
Bortezomib results in increased expression of GOSR2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:103,567,675...103,590,139
Ensembl chr11:103,567,675...103,588,724
|
|
G |
Gpank1 |
G patch domain and ankyrin repeats 1 |
increases expression |
ISO |
Bortezomib results in increased expression of GPANK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:35,340,472...35,343,791
Ensembl chr17:35,340,431...35,343,790
|
|
G |
Gpat3 |
glycerol-3-phosphate acyltransferase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of GPAT3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:100,994,095...101,046,968
Ensembl chr 5:100,993,579...101,046,968
|
|
G |
Gpatch2l |
G patch domain containing 2 like |
increases expression |
ISO |
Bortezomib results in increased expression of GPATCH2L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:86,288,569...86,341,439
Ensembl chr12:86,288,632...86,338,558
|
|
G |
Gphn |
gephyrin |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPHN mRNA |
CTD |
PMID:20977926 |
|
NCBI chr12:78,264,099...78,731,546
Ensembl chr12:78,273,153...78,731,546
|
|
G |
Gpr157 |
G protein-coupled receptor 157 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPR157 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:150,171,960...150,190,457
Ensembl chr 4:150,171,822...150,190,384
|
|
G |
Gpsm3 |
G-protein signalling modulator 3 (AGS3-like, C. elegans) |
decreases expression |
ISO |
Bortezomib results in decreased expression of GPSM3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:34,808,780...34,810,728
Ensembl chr17:34,808,780...34,810,728
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form |
CTD |
PMID:16118318 |
|
NCBI chr 7:24,927,683...24,937,276
Ensembl chr 7:24,927,683...24,937,276
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:16118318 PMID:24085292 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gspt1 |
G1 to S phase transition 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSPT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:11,034,104...11,072,189
Ensembl chr16:11,037,156...11,072,189
|
|
G |
Gsr |
glutathione reductase |
increases expression |
ISO |
Bortezomib results in increased expression of GSR mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gstcd |
glutathione S-transferase, C-terminal domain containing |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSTCD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:132,687,511...132,797,800
Ensembl chr 3:132,687,513...132,797,794
|
|
G |
Gstm4 |
glutathione S-transferase, mu 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GSTM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:107,937,887...107,952,495
Ensembl chr 3:107,947,724...107,952,210
|
|
G |
Gtf3c2 |
general transcription factor IIIC, polypeptide 2, beta |
decreases expression |
ISO |
Bortezomib results in decreased expression of GTF3C2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:31,313,350...31,337,488
Ensembl chr 5:31,313,349...31,337,488
|
|
G |
Gtpbp1 |
GTP binding protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of GTPBP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:79,574,202...79,605,680
Ensembl chr15:79,575,046...79,605,680
|
|
G |
Gzma |
granzyme A |
decreases expression |
ISO |
Bortezomib results in decreased expression of GZMA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:113,230,358...113,237,515
Ensembl chr13:113,230,359...113,237,515
|
|
G |
Gzmb |
granzyme B |
increases expression |
ISO |
Bortezomib results in increased expression of GZMB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:56,496,293...56,499,791
Ensembl chr14:56,496,295...56,499,717
|
|
G |
H2-DMb1 |
histocompatibility 2, class II, locus Mb1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HLA-DMB mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:34,372,165...34,379,203
Ensembl chr17:34,372,046...34,379,204
|
|
G |
H2-Ea |
histocompatibility 2, class II antigen E alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of HLA-DRA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:34,560,926...34,563,619
Ensembl chr17:34,560,926...34,563,618
|
|
G |
H2-Oa |
histocompatibility 2, O region alpha locus |
decreases expression |
ISO |
Bortezomib results in decreased expression of HLA-DOA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:34,311,353...34,314,286
Ensembl chr17:34,311,314...34,314,208
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases phosphorylation increases expression |
ISO |
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form] Bortezomib results in decreased phosphorylation of H2AX protein Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein] |
CTD |
PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
H3c10 |
H3 clustered histone 10 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr13:21,901,798...21,902,285
Ensembl chr13:21,901,829...21,902,239
|
|
G |
H6pd |
hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) |
decreases expression |
ISO |
Bortezomib results in decreased expression of H6PD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:150,063,931...150,093,480
Ensembl chr 4:150,063,932...150,093,480
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
increases expression |
ISO |
Bortezomib results in increased expression of HADHA mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:30,324,421...30,359,978
Ensembl chr 5:30,323,302...30,360,160
|
|
G |
Haus6 |
HAUS augmin-like complex, subunit 6 |
increases expression |
ISO |
Bortezomib results in increased expression of HAUS6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:86,497,092...86,530,317
Ensembl chr 4:86,497,092...86,530,292
|
|
G |
Hdac10 |
histone deacetylase 10 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HDAC10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:89,007,506...89,012,903
Ensembl chr15:89,007,510...89,012,903
|
|
G |
Hdac4 |
histone deacetylase 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HDAC4 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 1:91,856,501...92,123,424
Ensembl chr 1:91,856,501...92,123,421
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases response to substance |
ISO |
HDAC6 results in decreased susceptibility to Bortezomib |
CTD |
PMID:16585204 |
|
NCBI chr X:7,796,355...7,814,284
Ensembl chr X:7,796,359...7,814,128
|
|
G |
Hectd2 |
HECT domain E3 ubiquitin protein ligase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of HECTD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:36,531,420...36,598,535
Ensembl chr19:36,532,039...36,598,535
|
|
G |
Hecw1 |
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr13:14,401,023...14,697,874
Ensembl chr13:14,401,023...14,697,813
|
|
G |
Hexd |
hexosaminidase D |
decreases expression |
ISO |
Bortezomib results in decreased expression of HEXD mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:121,095,187...121,113,485
Ensembl chr11:121,095,259...121,113,481
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression |
ISO |
Bortezomib results in increased expression of HIF1A protein |
CTD |
PMID:16061869 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hikeshi |
heat shock protein nuclear import factor |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 7:89,567,893...89,590,446
Ensembl chr 7:89,566,737...89,590,412
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression increases response to substance |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein HMOX1 protein results in increased susceptibility to Bortezomib Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] |
CTD |
PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 PMID:35121005 More...
|
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions |
ISO |
abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] |
CTD |
PMID:19417023 |
|
NCBI chr16:4,544,225...4,584,606
Ensembl chr16:4,544,225...4,584,606
|
|
G |
Hnrnpll |
heterogeneous nuclear ribonucleoprotein L-like |
increases expression |
ISO |
Bortezomib results in increased expression of HNRNPLL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:80,336,916...80,369,697
Ensembl chr17:80,336,916...80,369,697
|
|
G |
Hoxa11 |
homeobox A11 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HOXA11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:52,219,086...52,222,784
Ensembl chr 6:52,219,086...52,222,790
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of HPS3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:20,050,109...20,089,478
Ensembl chr 3:20,050,109...20,089,479
|
|
G |
Hras |
Harvey rat sarcoma virus oncogene |
multiple interactions |
EXP |
ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:22842577 |
|
NCBI chr 7:140,770,839...140,773,938
Ensembl chr 7:140,769,018...140,773,918
|
|
G |
Hsf1 |
heat shock factor 1 |
increases expression increases activity multiple interactions |
ISO |
Bortezomib results in increased expression of HSF1 mRNA Bortezomib results in increased activity of HSF1 protein Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]; HSF1 protein promotes the reaction [Bortezomib results in increased expression of ZFAND2A protein] |
CTD |
PMID:17895889 PMID:23874968 PMID:24619424 PMID:31540997 |
|
NCBI chr15:76,361,562...76,385,355
Ensembl chr15:76,361,622...76,386,113
|
|
G |
Hsf2 |
heat shock factor 2 |
multiple interactions increases expression |
ISO |
HSF2 protein inhibits the reaction [Bortezomib results in increased expression of ZFAND2A protein] Bortezomib results in increased expression of HSF2 mRNA; Bortezomib results in increased expression of HSF2 protein |
CTD |
PMID:24619424 |
|
NCBI chr10:57,359,862...57,389,239
Ensembl chr10:57,362,481...57,389,231
|
|
G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
increases expression decreases expression |
ISO |
Bortezomib results in increased expression of HSP90AA1 mRNA Bortezomib results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:17895889 PMID:20471514 PMID:20830808 |
|
NCBI chr12:110,657,470...110,662,829
Ensembl chr12:110,657,039...110,669,162
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
|
|
G |
Hspa1a |
heat shock protein 1A |
multiple interactions decreases response to substance increases expression |
ISO |
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter] HSPA1A protein results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of HSPA1A mRNA |
CTD |
PMID:17895889 PMID:23874968 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa1b |
heat shock protein 1B |
increases expression affects response to substance decreases response to substance |
ISO |
Bortezomib results in increased expression of HSPA1B mRNA HSPA1B protein affects the susceptibility to Bortezomib HSPA1B protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:15509775 PMID:17895889 PMID:23874968 |
|
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
|
|
G |
Hspa4l |
heat shock protein 4 like |
increases expression |
ISO |
Bortezomib results in increased expression of HSPA4L mRNA |
CTD |
PMID:20830808 |
|
NCBI chr 3:40,698,664...40,750,538
Ensembl chr 3:40,699,814...40,750,538
|
|
G |
Hspa5 |
heat shock protein 5 |
multiple interactions increases expression decreases response to substance |
ISO EXP |
Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein] Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein HSPA5 results in decreased susceptibility to Bortezomib |
CTD |
PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 PMID:18723477 PMID:20110775 PMID:20546536 PMID:20977926 PMID:21762082 PMID:24291039 More...
|
|
NCBI chr 2:34,662,102...34,666,541
Ensembl chr 2:34,661,982...34,667,559
|
|
G |
Hspb1 |
heat shock protein 1 |
increases expression decreases response to substance |
ISO |
Bortezomib results in increased expression of HSPB1 mRNA HSPB1 protein results in decreased susceptibility to Bortezomib |
CTD |
PMID:14559800 PMID:20830808 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hsph1 |
heat shock 105kDa/110kDa protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of HSPH1 mRNA |
CTD |
PMID:17898295 |
|
NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
|
|
G |
Htr2b |
5-hydroxytryptamine (serotonin) receptor 2B |
decreases expression |
ISO |
Bortezomib results in decreased expression of HTR2B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:86,025,268...86,043,960
Ensembl chr 1:86,026,748...86,039,692
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
Bortezomib affects the localization of HTRA2 protein |
CTD |
PMID:16024631 |
|
NCBI chr 6:83,028,247...83,031,552
Ensembl chr 6:83,028,247...83,032,254
|
|
G |
Ibtk |
inhibitor of Bruton agammaglobulinemia tyrosine kinase |
increases expression |
ISO |
Bortezomib results in increased expression of IBTK mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:85,569,412...85,632,756
Ensembl chr 9:85,569,413...85,631,387
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein Bortezomib results in decreased expression of ICAM1 mRNA |
CTD |
PMID:18223231 PMID:20471514 PMID:25913414 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Ide |
insulin degrading enzyme |
increases expression |
ISO |
Bortezomib results in increased expression of IDE mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:37,246,140...37,341,664
Ensembl chr19:37,246,142...37,340,010
|
|
G |
Idh3a |
isocitrate dehydrogenase 3 (NAD+) alpha |
decreases expression |
ISO |
Bortezomib results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945
|
|
G |
Ifi44 |
interferon-induced protein 44 |
increases expression |
ISO |
Bortezomib results in increased expression of IFI44 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:151,436,559...151,455,580
Ensembl chr 3:151,436,559...151,455,597
|
|
G |
Ifitm1 |
interferon induced transmembrane protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IFITM1 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 7:140,547,342...140,549,740
Ensembl chr 7:140,547,134...140,549,738
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] |
CTD |
PMID:30482226 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Ifrd2 |
interferon-related developmental regulator 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IFRD2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:107,464,917...107,470,237
Ensembl chr 9:107,464,841...107,470,584
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
increases response to substance |
ISO |
IGF1R gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions decreases response to substance |
ISO |
Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein] Bortezomib results in decreased susceptibility to IGF2 protein |
CTD |
PMID:24055520 |
|
NCBI chr 7:142,204,505...142,220,566
Ensembl chr 7:142,204,503...142,220,553
|
|
G |
Igll1 |
immunoglobulin lambda-like polypeptide 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IGLL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr16:16,678,535...16,681,849
Ensembl chr16:16,678,535...16,681,849
|
|
G |
Ikbkb |
inhibitor of kappaB kinase beta |
multiple interactions decreases expression |
ISO |
Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Bortezomib results in decreased expression of IKBKB mRNA |
CTD |
PMID:19417023 PMID:20471514 PMID:24085292 |
|
NCBI chr 8:23,149,228...23,196,605
Ensembl chr 8:23,149,228...23,196,605
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IKZF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:11,634,970...11,722,930
Ensembl chr11:11,634,980...11,722,926
|
|
G |
Il10 |
interleukin 10 |
affects expression |
ISO |
Bortezomib affects the expression of IL10 protein |
CTD |
PMID:19922463 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il15 |
interleukin 15 |
increases expression |
ISO |
Bortezomib results in increased expression of IL15 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:83,058,253...83,129,883
Ensembl chr 8:83,058,261...83,129,851
|
|
G |
Il18r1 |
interleukin 18 receptor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of IL18R1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 1:40,504,712...40,540,014
Ensembl chr 1:40,504,712...40,540,014
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of IL1B mRNA Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il1r1 |
interleukin 1 receptor, type I |
increases expression |
ISO |
Bortezomib results in increased expression of IL1R1 mRNA |
CTD |
PMID:17895889 |
|
NCBI chr 1:40,261,651...40,355,361
Ensembl chr 1:40,264,240...40,356,417
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
increases expression |
ISO |
Bortezomib results in increased expression of IL23A mRNA |
CTD |
PMID:17895889 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases secretion decreases expression increases expression |
ISO EXP |
[Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone] Bortezomib results in decreased secretion of IL6 protein Bortezomib results in decreased expression of IL6 mRNA Bortezomib results in increased expression of IL6 mRNA Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA] |
CTD |
PMID:17895889 PMID:23063726 PMID:28134560 PMID:35121005 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression multiple interactions |
ISO |
Bortezomib results in increased expression of IL7R mRNA [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA |
CTD |
PMID:20471514 PMID:25522274 |
|
NCBI chr15:9,505,880...9,530,270
Ensembl chr15:9,505,874...9,530,262
|
|
G |
Ino80b |
INO80 complex subunit B |
decreases expression |
ISO |
Bortezomib results in decreased expression of INO80B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:83,098,746...83,102,100
Ensembl chr 6:83,098,746...83,102,412
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr X:73,057,520...73,067,527
Ensembl chr X:73,057,520...73,067,524
|
|
G |
Irak2 |
interleukin-1 receptor-associated kinase 2 |
increases expression |
ISO |
Bortezomib results in increased expression of IRAK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:113,615,428...113,671,987
Ensembl chr 6:113,615,428...113,671,987
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression multiple interactions |
ISO |
Bortezomib results in decreased expression of IRF4 protein 3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of IRF4 protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of IRF4 protein] |
CTD |
PMID:37657595 |
|
NCBI chr13:30,933,191...30,950,965
Ensembl chr13:30,933,209...30,950,959
|
|
G |
Irs1 |
insulin receptor substrate 1 |
decreases degradation |
ISO |
Bortezomib results in decreased degradation of IRS1 protein |
CTD |
PMID:16227402 |
|
NCBI chr 1:82,210,826...82,269,160
Ensembl chr 1:82,210,822...82,269,137
|
|
G |
Isca1 |
iron-sulfur cluster assembly 1 |
increases expression |
ISO |
Bortezomib results in increased expression of ISCA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:59,903,229...59,917,603
Ensembl chr13:59,903,223...59,917,624
|
|
G |
Itga6 |
integrin alpha 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of ITGA6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:71,617,236...71,688,761
Ensembl chr 2:71,575,960...71,688,760
|
|
G |
Itgal |
integrin alpha L |
decreases expression |
ISO |
Bortezomib results in decreased expression of ITGAL mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:126,895,404...126,934,309
Ensembl chr 7:126,895,432...126,934,310
|
|
G |
Itgav |
integrin alpha V |
multiple interactions increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA Bortezomib results in increased expression of ITGAV mRNA |
CTD |
PMID:20471514 PMID:25913414 |
|
NCBI chr 2:83,554,796...83,637,261
Ensembl chr 2:83,554,741...83,637,260
|
|
G |
Itgb6 |
integrin beta 6 |
increases expression |
ISO |
Bortezomib results in increased expression of ITGB6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:60,428,636...60,553,005
Ensembl chr 2:60,428,636...60,552,987
|
|
G |
Jak1 |
Janus kinase 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of JAK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:101,009,171...101,122,493
Ensembl chr 4:101,009,564...101,122,479
|
|
G |
Jun |
jun proto-oncogene |
multiple interactions decreases expression increases phosphorylation increases expression |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein] Bortezomib results in decreased expression of JUN mRNA Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form |
CTD |
PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 PMID:17898295 PMID:20471514 PMID:20830808 PMID:25913414 More...
|
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Junb |
jun B proto-oncogene |
multiple interactions decreases expression |
ISO |
3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid promotes the reaction [Bortezomib results in decreased expression of JUNB protein]; Bortezomib promotes the reaction [3-(5-(4-(cyclopentyloxy)-2-hydroxybenzoyl)-2-((3-hydroxy-1,2-benzisoxazol-6-yl)methoxy)phenyl)propionic acid results in decreased expression of JUNB protein] |
CTD |
PMID:37657595 |
|
NCBI chr 8:85,703,538...85,705,377
Ensembl chr 8:85,701,113...85,705,347
|
|
G |
Jund |
jun D proto-oncogene |
decreases expression |
ISO |
Bortezomib results in decreased expression of JUND mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kat2b |
K(lysine) acetyltransferase 2B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KAT2B mRNA |
CTD |
PMID:20471514 |
|
NCBI chr17:53,873,802...53,979,749
Ensembl chr17:53,873,889...53,979,748
|
|
G |
Kat6b |
K(lysine) acetyltransferase 6B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KAT6B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:21,549,284...21,722,546
Ensembl chr14:21,531,502...21,722,546
|
|
G |
Katnal1 |
katanin p60 subunit A-like 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KATNAL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:148,808,394...148,865,978
Ensembl chr 5:148,808,394...148,931,957
|
|
G |
Kcmf1 |
potassium channel modulatory factor 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KCMF1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:72,818,097...72,876,962
Ensembl chr 6:72,818,097...72,876,962
|
|
G |
Kctd10 |
potassium channel tetramerisation domain containing 10 |
increases expression |
ISO |
Bortezomib results in increased expression of KCTD10 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:114,501,633...114,518,566
Ensembl chr 5:114,501,628...114,518,569
|
|
G |
Kdelr1 |
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDELR1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:45,522,264...45,533,150
Ensembl chr 7:45,522,196...45,533,156
|
|
G |
Kdm4b |
lysine (K)-specific demethylase 4B |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDM4B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:56,632,975...56,710,774
Ensembl chr17:56,633,062...56,709,870
|
|
G |
Kdm5c |
lysine demethylase 5C |
decreases expression |
ISO |
Bortezomib results in decreased expression of KDM5C mRNA |
CTD |
PMID:20977926 |
|
NCBI chr X:151,015,698...151,062,098
Ensembl chr X:151,016,016...151,057,531
|
|
G |
Kdr |
kinase insert domain protein receptor |
multiple interactions |
ISO |
[Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein |
CTD |
PMID:16985072 |
|
NCBI chr 5:76,093,487...76,139,880
Ensembl chr 5:76,093,487...76,139,118
|
|
G |
Kif22 |
kinesin family member 22 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIF22 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:126,626,901...126,641,639
Ensembl chr 7:126,626,901...126,641,643
|
|
G |
Kif9 |
kinesin family member 9 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIF9 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:110,306,062...110,354,242
Ensembl chr 9:110,306,026...110,354,247
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KIFC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:34,094,640...34,109,607
Ensembl chr17:34,094,633...34,109,635
|
|
G |
Klf6 |
Kruppel-like transcription factor 6 |
increases expression |
ISO |
Bortezomib results in increased expression of KLF6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:5,911,488...5,920,392
Ensembl chr13:5,911,481...5,920,393
|
|
G |
Klhdc7b |
kelch domain containing 7B |
increases expression |
ISO |
Bortezomib results in increased expression of KLHDC7B mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:89,268,262...89,274,025
Ensembl chr15:89,269,120...89,273,070
|
|
G |
Klhl20 |
kelch-like 20 |
increases expression |
ISO |
Bortezomib results in increased expression of KLHL20 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:160,915,945...160,959,078
Ensembl chr 1:160,915,945...160,959,081
|
|
G |
Klrk1 |
killer cell lectin-like receptor subfamily K, member 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of KLRK1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:129,587,286...129,600,863
Ensembl chr 6:129,587,286...129,600,827
|
|
G |
Kmt2a |
lysine (K)-specific methyltransferase 2A |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 9:44,714,652...44,793,492
Ensembl chr 9:44,714,652...44,792,594
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
increases expression |
ISO |
Bortezomib results in increased expression of KPNA2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:106,879,455...106,890,351
Ensembl chr11:106,879,455...106,890,367
|
|
G |
Kri1 |
KRI1 homolog |
increases expression |
ISO |
Bortezomib results in increased expression of KRI1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:21,184,753...21,199,265
Ensembl chr 9:21,184,753...21,199,265
|
|
G |
Krit1 |
KRIT1, ankyrin repeat containing |
increases expression |
ISO |
Bortezomib results in increased expression of KRIT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:3,853,156...3,894,515
Ensembl chr 5:3,853,184...3,895,564
|
|
G |
Ktn1 |
kinectin 1 |
increases expression |
ISO |
Bortezomib results in increased expression of KTN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:47,886,551...47,974,021
Ensembl chr14:47,885,905...47,977,351
|
|
G |
Lgals2 |
lectin, galactose-binding, soluble 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LGALS2 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr15:78,735,060...78,739,729
Ensembl chr15:78,735,060...78,739,729
|
|
G |
Lgals8 |
lectin, galactose binding, soluble 8 |
increases expression |
ISO |
Bortezomib results in increased expression of LGALS8 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr13:12,454,283...12,479,857
Ensembl chr13:12,454,296...12,479,825
|
|
G |
Lgr4 |
leucine-rich repeat-containing G protein-coupled receptor 4 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr 2:109,747,919...109,844,602
Ensembl chr 2:109,747,992...109,844,602
|
|
G |
Lig4 |
ligase IV, DNA, ATP-dependent |
increases expression |
ISO |
Bortezomib results in increased expression of LIG4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:10,020,020...10,027,680
Ensembl chr 8:10,019,049...10,027,686
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMA1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:99,676,351...99,773,292
Ensembl chr15:99,676,351...99,773,337
|
|
G |
Limd1 |
LIM domains containing 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:123,306,790...123,350,617
Ensembl chr 9:123,307,771...123,350,617
|
|
G |
Lims1 |
LIM and senescent cell antigen-like domains 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LIMS1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:58,159,164...58,260,513
Ensembl chr10:58,159,288...58,260,513
|
|
G |
Lmna |
lamin A |
increases cleavage |
ISO |
Bortezomib results in increased cleavage of LMNA protein |
CTD |
PMID:20110775 |
|
NCBI chr 3:88,388,455...88,413,842
Ensembl chr 3:88,387,454...88,417,263
|
|
G |
Lrfn4 |
leucine rich repeat and fibronectin type III domain containing 4 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LRFN4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:4,661,817...4,665,720
Ensembl chr19:4,661,813...4,665,695
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LRRC41 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 4:115,932,466...115,954,306
Ensembl chr 4:115,932,466...115,954,240
|
|
G |
Lrrfip1 |
leucine rich repeat (in FLII) interacting protein 1 |
increases expression |
ISO |
Bortezomib results in increased expression of LRRFIP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:90,924,652...91,056,666
Ensembl chr 1:90,926,459...91,056,666
|
|
G |
Lsm4 |
LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated |
decreases expression |
ISO |
Bortezomib results in decreased expression of LSM4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 8:71,124,663...71,131,402
Ensembl chr 8:71,125,898...71,131,402
|
|
G |
Lst1 |
leukocyte specific transcript 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of LST1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:35,404,071...35,407,416
Ensembl chr17:35,404,071...35,407,415
|
|
G |
Luc7l |
Luc7-like |
increases expression |
ISO |
Bortezomib results in increased expression of LUC7L mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:26,471,874...26,504,484
Ensembl chr17:26,471,870...26,504,478
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA |
CTD |
PMID:25913414 |
|
NCBI chr 1:16,758,680...16,779,829
Ensembl chr 1:16,758,275...16,779,835
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein |
CTD |
PMID:15039284 |
|
NCBI chr 4:3,676,865...3,791,613
Ensembl chr 4:3,678,115...3,813,122
|
|
G |
Maf1 |
MAF1 homolog, negative regulator of RNA polymerase III |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] |
CTD |
PMID:31645432 |
|
NCBI chr15:76,235,494...76,238,578
Ensembl chr15:76,235,494...76,238,580
|
|
G |
Mafg |
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian) |
increases expression |
ISO |
Bortezomib results in increased expression of MAFG mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:120,515,943...120,525,771
Ensembl chr11:120,515,943...120,524,426
|
|
G |
Malat1 |
metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) |
increases expression |
ISO |
Bortezomib results in increased expression of MALAT1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:5,845,718...5,852,700
Ensembl chr19:5,845,717...5,853,602
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24085292 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map2k1 |
mitogen-activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein |
CTD |
PMID:12893773 |
|
NCBI chr 9:64,093,066...64,160,887
Ensembl chr 9:64,093,052...64,160,913
|
|
G |
Map2k2 |
mitogen-activated protein kinase kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAP2K2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:80,941,749...80,960,531
Ensembl chr10:80,941,749...80,969,809
|
|
G |
Map2k4 |
mitogen-activated protein kinase kinase 4 |
multiple interactions |
ISO |
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein |
CTD |
PMID:15039284 |
|
NCBI chr11:65,579,070...65,679,185
Ensembl chr11:65,579,069...65,679,123
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:110,289,928...110,416,348
Ensembl chr11:110,289,948...110,416,348
|
|
G |
Map4k3 |
mitogen-activated protein kinase kinase kinase kinase 3 |
increases expression |
ISO |
Bortezomib results in increased expression of MAP4K3 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:80,887,942...81,039,118
Ensembl chr17:80,887,941...81,035,914
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
increases expression |
ISO |
Bortezomib results in increased expression of MAP4K4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:39,939,806...40,065,470
Ensembl chr 1:39,940,073...40,065,470
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions increases expression increases phosphorylation decreases activity |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein] Bortezomib results in decreased activity of MAPK1 protein |
CTD |
PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk10 |
mitogen-activated protein kinase 10 |
multiple interactions |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] |
CTD |
PMID:15173093 |
|
NCBI chr 5:103,056,413...103,359,200
Ensembl chr 5:103,055,814...103,359,200
|
|
G |
Mapk14 |
mitogen-activated protein kinase 14 |
multiple interactions |
ISO |
[Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] |
CTD |
PMID:12893773 PMID:18790767 |
|
NCBI chr17:28,910,316...28,967,379
Ensembl chr17:28,910,303...28,967,380
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions increases expression increases phosphorylation decreases activity |
ISO |
[Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein] Bortezomib results in decreased activity of MAPK3 protein |
CTD |
PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] evodiamine inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 PMID:38010754 More...
|
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation multiple interactions |
ISO |
Bortezomib results in increased phosphorylation of MAPK9 protein [Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] |
CTD |
PMID:16985072 PMID:18559525 PMID:18718063 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapkap1 |
mitogen-activated protein kinase associated protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAPKAP1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:34,296,783...34,514,970
Ensembl chr 2:34,296,783...34,514,962
|
|
G |
Mapkapk2 |
MAP kinase-activated protein kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAPKAPK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:130,981,437...131,025,580
Ensembl chr 1:130,981,437...131,025,563
|
|
G |
Mark2 |
MAP/microtubule affinity regulating kinase 2 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MARK2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr19:7,252,761...7,319,222
Ensembl chr19:7,252,761...7,319,225
|
|
G |
Maz |
MYC-associated zinc finger protein (purine-binding transcription factor) |
decreases expression |
ISO |
Bortezomib results in decreased expression of MAZ mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:126,621,306...126,626,177
Ensembl chr 7:126,621,302...126,626,209
|
|
G |
Mbd1 |
methyl-CpG binding domain protein 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBD1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:74,400,676...74,415,808
Ensembl chr18:74,400,676...74,415,803
|
|
G |
Mbd4 |
methyl-CpG binding domain protein 4 |
increases expression |
ISO |
Bortezomib results in increased expression of MBD4 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:115,817,658...115,830,361
Ensembl chr 6:115,817,658...115,830,332
|
|
G |
Mbl2 |
mannose-binding lectin (protein C) 2 |
increases response to substance |
ISO |
MBL2 gene SNP results in increased susceptibility to Bortezomib |
CTD |
PMID:20864405 |
|
NCBI chr19:30,210,306...30,217,087
Ensembl chr19:30,210,342...30,217,087
|
|
G |
Mbnl1 |
muscleblind like splicing regulator 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBNL1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:60,380,209...60,537,171
Ensembl chr 3:60,380,251...60,537,171
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Bortezomib results in decreased expression of MBP mRNA |
CTD |
PMID:20977926 |
|
NCBI chr18:82,492,883...82,603,762
Ensembl chr18:82,493,271...82,603,762
|
|
G |
Mcl1 |
myeloid cell leukemia sequence 1 |
multiple interactions increases expression decreases response to substance increases cleavage |
ISO EXP |
[[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein] Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein] MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein |
CTD |
PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 PMID:18566236 PMID:18625202 PMID:19100720 PMID:20051518 PMID:21195056 PMID:21345073 PMID:25752611 PMID:26769846 More...
|
|
NCBI chr 3:95,564,017...95,583,553
Ensembl chr 3:95,566,099...95,570,487
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MCM7 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 5:138,162,845...138,170,675
Ensembl chr 5:138,162,845...138,170,684
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MDC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:36,152,390...36,170,562
Ensembl chr17:36,152,407...36,170,562
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
multiple interactions increases cleavage affects expression |
ISO |
[CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein] Bortezomib affects the expression of MDM2 protein |
CTD |
PMID:12393500 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
increases expression |
ISO |
Bortezomib results in increased expression of ME1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 9:86,463,416...86,577,967
Ensembl chr 9:86,463,424...86,578,006
|
|
G |
Mettl21a |
methyltransferase 21A, HSPA lysine |
increases expression |
ISO |
Bortezomib results in increased expression of METTL21A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:64,645,632...64,661,926
Ensembl chr 1:64,645,632...64,656,401
|
|
G |
Mettl27 |
methyltransferase like 27 |
decreases expression |
ISO |
Bortezomib results in decreased expression of METTL27 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 5:134,961,158...134,971,491
Ensembl chr 5:134,961,222...134,971,491
|
|
G |
Mex3d |
mex3 RNA binding family member D |
decreases expression |
ISO |
Bortezomib results in decreased expression of MEX3D mRNA |
CTD |
PMID:20977926 |
|
NCBI chr10:80,216,189...80,223,485
Ensembl chr10:80,216,189...80,223,493
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MFN1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:32,583,594...32,633,384
Ensembl chr 3:32,583,614...32,633,388
|
|
G |
Mfng |
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
decreases expression |
ISO |
Bortezomib results in decreased expression of MFNG mRNA |
CTD |
PMID:20977926 |
|
NCBI chr15:78,640,082...78,657,678
Ensembl chr15:78,640,082...78,657,675
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions |
ISO |
Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] |
CTD |
PMID:24193513 |
|
NCBI chr 7:136,496,315...136,732,001
Ensembl chr 7:136,496,343...136,731,995
|
|
G |
Mir21a |
microRNA 21a |
increases expression |
ISO |
Bortezomib results in increased expression of MIR21 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mir568 |
microRNA 568 |
multiple interactions |
ISO |
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA |
CTD |
PMID:25522274 |
|
NCBI chr16:43,461,018...43,461,100
Ensembl chr16:43,461,018...43,461,100
|
|
G |
Mki67 |
antigen identified by monoclonal antibody Ki 67 |
decreases expression multiple interactions |
ISO EXP |
Bortezomib results in decreased expression of MKI67 protein [Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] |
CTD |
PMID:19372569 PMID:30482226 |
|
NCBI chr 7:135,291,513...135,318,286
Ensembl chr 7:135,291,513...135,318,090
|
|
G |
Mllt11 |
myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11 |
increases expression |
ISO |
Bortezomib results in increased expression of MLLT11 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:95,125,852...95,139,486
Ensembl chr 3:95,126,446...95,139,482
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [capillarisin results in decreased expression of MMP9 protein] |
CTD |
PMID:20696233 PMID:24333736 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mob3a |
MOB kinase activator 3A |
decreases expression |
ISO |
Bortezomib results in decreased expression of MOB3A mRNA |
CTD |
PMID:17659339 |
|
NCBI chr10:80,521,087...80,537,845
Ensembl chr10:80,521,087...80,537,811
|
|
G |
Morc2a |
microrchidia 2A |
increases expression |
ISO |
Bortezomib results in increased expression of MORC2 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr11:3,599,132...3,640,477
Ensembl chr11:3,599,191...3,640,477
|
|
G |
Mpz |
myelin protein zero |
decreases expression |
ISO EXP |
Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein |
CTD |
PMID:20830808 |
|
NCBI chr 1:170,978,282...170,988,699
Ensembl chr 1:170,978,280...170,988,699
|
|
G |
Mrpl19 |
mitochondrial ribosomal protein L19 |
increases expression |
ISO |
Bortezomib results in increased expression of MRPL19 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 6:81,934,807...81,942,930
Ensembl chr 6:81,934,832...81,942,939
|
|
G |
Mrpl30 |
mitochondrial ribosomal protein L30 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPL30 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 1:37,929,558...37,937,419
Ensembl chr 1:37,929,558...37,937,616
|
|
G |
Mrps12 |
mitochondrial ribosomal protein S12 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPS12 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 7:28,439,066...28,441,246
Ensembl chr 7:28,439,066...28,441,245
|
|
G |
Mrps5 |
mitochondrial ribosomal protein S5 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MRPS5 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 2:127,429,346...127,445,906
Ensembl chr 2:127,429,142...127,448,749
|
|
G |
Msh6 |
mutS homolog 6 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MSH6 mRNA |
CTD |
PMID:17659339 |
|
NCBI chr17:88,282,478...88,298,320
Ensembl chr17:88,282,490...88,298,320
|
|
G |
Mtmr6 |
myotubularin related protein 6 |
increases expression |
ISO |
Bortezomib results in increased expression of MTMR6 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr14:60,488,941...60,539,820
Ensembl chr14:60,502,677...60,539,819
|
|
G |
Muc1 |
mucin 1, transmembrane |
decreases expression |
ISO |
Bortezomib results in decreased expression of MUC1 mRNA |
CTD |
PMID:20977926 |
|
NCBI chr 3:89,136,363...89,140,688
Ensembl chr 3:89,136,364...89,140,688
|
|
G |
Mutyh |
mutY DNA glycosylase |
decreases expression |
ISO |
Bortezomib results in decreased expression of MUTYH mRNA |
CTD |
PMID:17659339 |
|
NCBI chr 4:116,664,846...116,676,641
Ensembl chr 4:116,664,920...116,676,637
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions increases expression decreases expression |
ISO |
[Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein] Bortezomib results in increased expression of MYC protein Bortezomib results in decreased expression of MYC protein |
CTD |
PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
decreases expression |
ISO |
Bortezomib results in decreased expression of MYD88 mRNA |
CTD |
PMID:20471514 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Myl12a |
myosin, light chain 12A, regulatory, non-sarcomeric |
increases expression |
ISO |
Bortezomib results in increased expression of MYL12A mRNA |
CTD |
PMID:20977926 |
|
NCBI chr17:71,300,788...71,309,528
Ensembl chr17:71,300,651...71,309,873
|
|
G |
| |